#### Check for updates

#### **OPEN ACCESS**

EDITED BY Muaz Belviranli, Selçuk University, Türkiye

#### REVIEWED BY Alexios Batrakoulis, University of Thessaly, Greece Kayvan Khoramipour, Kerman University of Medical Sciences, Iran

\*CORRESPONDENCE Chou Wang,

🛛 W1686474992@outlook.com

RECEIVED 14 September 2024 ACCEPTED 09 December 2024 PUBLISHED 23 December 2024

#### CITATION

Wang C and Tang S (2024) The effects of aerobic exercise on 24-hour mean blood glucose levels measured by continuous glucose monitoring in type 2 diabetes: a meta-analysis. *Front. Physiol.* 15:1496271. doi: 10.3389/fphys.2024.1496271

#### COPYRIGHT

© 2024 Wang and Tang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

## The effects of aerobic exercise on 24-hour mean blood glucose levels measured by continuous glucose monitoring in type 2 diabetes: a meta-analysis

### Chou Wang<sup>1</sup>\* and Shaokai Tang<sup>2</sup>

<sup>1</sup>School of Sport, Health and Exercise, Loughborough University, Loughborough, United Kingdom, <sup>2</sup>College of Sports Science, Jishou University, Jishou, China

**Purpose:** To examine the effects of structured aerobic exercise on 24-hour mean blood glucose outcomes assessed by continuous glucose monitors in adults with type 2 diabetes.

**Methods:** The study established specific inclusion and exclusion criteria and conducted a comprehensive search across five databases, including PubMed, Web of Science, Embase, Cochrane Library, and EBSCOhost from the start year of each database's coverage to 22 July 2024. The quality of the included studies was evaluated using the Cochrane Handbook 5.1 guidelines. Data analysis was performed using Review Manager 5.4 to determine effect sizes, conduct sensitivity analyses, assess potential biases, and perform subgroup analyses.

Results: A total of 1,034 articles were retrieved, and after 4 rounds of screening, 13 articles were finally selected for meta-analysis. The study included 626 participants (30% female; mean <u>+</u> SD: age, 59.4 <u>+</u> 6.4 years; BMI, 29.61 <u>+</u> 2.24 kg/m<sup>2</sup>), including 330 in the experimental group and 296 in the control group. The results of the meta-analysis showed that aerobic exercise can improve the 24-hour mean blood glucose in patients with T2DM (d = -0.65, 95% CI: -0.75 to -0.55, p < 0.05). Subgroup analysis showed that moderateintensity and high-intensity aerobic exercise can improve the 24-hour mean blood glucose in patients with T2DM (d = -0.71, 95% CI: -0.81 to -0.60, p < 0.05), (d = -0.60, 95% CI: -0.98 to -0.22, p < 0.05). Also, 20-40 min and 40-60 min of aerobic exercise per session can improve the 24-hour average blood glucose in patients with T2DM (d = -0.75, 95% CI: -0.91 to -0.59, p < 0.05), (d = -0.59, 95% CI: -0.71 to -0.46, p < 0.05). Aerobic exercise can improve the 24-hour mean blood glucose in patients with T2DM who have a body mass index (BMI) between 29 and 30 kg/m<sup>2</sup>, as well as those with a BMI greater than 30 kg/m<sup>2</sup> (d = -0.65, 95% CI: -0.94 to -0.36, p < 0.05), (d = -0.76, 95% CI: -0.87 to -0.64, p < 0.05).

**Conclusion:** Aerobic exercise can improve the 24-hour mean blood glucose in patients with T2DM. Additionally, 20–60 min of aerobic exercise with moderate intensity, and high intensity can improve the 24-hour mean blood glucose in patients with T2DM who have a BMI greater than 29 kg/m<sup>2</sup>.

Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifer PROSPERO CRD42024590812

KEYWORDS

meta-analysis, T2DM, aerobic exercise, 24-hour mean glucose, CGM

### 1 Introduction

Diabetes has become a global health problem. By 2030, it is projected that 11.3% of the global population will have diabetes (Zhang et al., 2023). Complications arising from diabetes, including cardiovascular disease, kidney disease, and retinopathy, are closely related to blood glucose fluctuations (Sartore et al., 2023). Maintaining stable blood sugar levels throughout the day is crucial for the long-term health of patients. The 24-hour mean blood glucose is the average of blood glucose levels measured over a 24-hour period, often obtained using continuous glucose monitor (CGM) devices. These devices can measure blood glucose levels every 5 min, and long-term use allows patients to collect a large amount of blood glucose data over 24 h (Edelman et al., 2018). Compared to other diagnostic indicators for diabetes, CGM devices offer advantages such as large-scale data collection, convenient operation, and real-time monitoring.

Dietary, pharmacological, and exercise interventions are common methods to control blood glucose levels in patients with type 2 diabetes mellitus (T2DM) (Zhang et al., 2023). T2DM occurs due to the body's inability to use insulin effectively and accounts for 90% of diabetes cases globally (Wu et al., 2020). Dietary interventions often require strict control of food types and calorie intake, which can be challenging to maintain long-term. Pharmacological interventions require regular medication use, which can lead to dependency and side effects (Remelli et al., 2022). Exercise interventions, however, are flexible, convenient, and can be easily incorporated into daily routines. Resistance exercises help strengthen muscles, but they pose a risk of injury to beginners and older adults. Taijiquan, a traditional Chinese mind-body exercises, is beneficial for balance, cardiovascular and respiratory function (Li et al., 2024). However, it is complex and requires time to learn and master. Aerobic exercise, consistently ranked among the top 20 global fitness trends in the 2024 ACSM Worldwide Fitness Trends report, is one of the most widely recommended safe and highly efficient interventions for enhancing cardiometabolic health (A'Naja et al., 2024; Batrakoulis et al., 2022a). Among them, high intensity interval training (HIIT), is especially efficient in improving physical health, including highly cardiorespiratory fitness, and psychological health, such as increased quality of life and enjoyment in exercise (Batrakoulis et al., 2021; Batrakoulis and Fatouros, 2022). These physical and psychological benefits brought by aerobic exercise make it a ideal intervention for managing chronic conditions such as T2DM.

Current studies present conflicting opinions regarding the effect of aerobic exercise on 24-hour average blood glucose. Oberlin et al. (2014) reported that a single 60-minute aerobic exercise session can significantly improve the 24-hour mean blood glucose in patients with T2DM, from 6.62 to 5.98 mmol/L. Additionally, the area under the blood glucose curve after lunch was markedly reduced following exercise compared to the control group. In contrast, Rees et al. (2019) found while a single session of fast walking significantly decreased blood glucose levels during the exercise by 1.56 mmol/L in middle-aged and elderly T2DM patients, it did not significantly change the 24-hour average blood glucose, fasting blood glucose (FBG), postprandial blood glucose, or blood glucose variability compared to the control. These findings suggest that variations in exercise type, duration, and intensity may account for the differences in 24-hour average blood glucose results observed in aerobic exercise studies involving patients with T2DM.

Based on this, a meta-analysis was conducted to assess the effect of aerobic exercise on 24-hour mean blood glucose levels measured using CGM in patients with T2DM. This analysis aims to clarify the effects of different exercise periods, intensities, frequencies, and duration on the 24-hour mean blood glucose of T2DM patients with different BMIs. The findings will provide valuable insights and references for future research on blood glucose management in patients with T2DM.

### 2 Method

### 2.1 Search strategy

Searches were conducted in PubMed, Web of Science, Embase, Cochrane Library, and EBSCOhost from the start year of each database's coverage to 22 July 2024. The search strategy employed a combination of subject terms and free terms. The search terms are presented in Table 1. The search terms were divided into three groups based on intervention method, research subject, and outcome indicator, with terms within each group connected by OR. The groups are then combined using AND. After the literature search, two researchers independently screened the articles in a double blend manner. The search results were imported into EndNote 21 literature management software, where duplicate records were identified and removed by reviewing the titles and abstracts. Subsequently, the full texts were downloaded and reviewed for data extraction. This process was also conducted independently by two researchers. In cases of disagreement, a third researcher was consulted to resolve whether to include the study.

### 2.2 Inclusion and exclusion criteria

#### 2.2.1 Inclusion criteria

Study participants: Eligible participants were adult patients with T2DM, aged 18 years or older.

Study intervention: Studies were included if they clearly defined the exercise period, intensity, frequency, and duration of structured exercise and reported the effects of these parameters. Articles that merely encouraged participants to become more active or participate in sports without providing a substantially structured exercise program or exercise monitoring (e.g., direct supervision or a logbook) were excluded.

#### TABLE 1 Search terms and search formulas.

Search term classification	Search term
Intervention method	Exercise [Mesh] or Exercises or Exercise, Physical or Exercises, Physical or Physical Exercise or Physical Exercises or Physical Activity or Activities, Physical or Activity, Physical or Physical Activities or Exercise, Aerobic or Aerobic Exercise or Aerobic Exercises or Exercises, Isometric or Isometric or Isometric Exercises or Isometric Exercise or Acute Exercises or Acute Exercises or Exercise, Acute or Exercises, Acute or Exercise Training or Exercise Trainings, Exercise or Training, Exercise or Trainings, Exercise
Research subject	Diabetes Mellitus, Type 2 [Mesh] or Diabetes Mellitus, Adult-Onset or Adult-Onset Diabetes Mellitus or Diabetes Mellitus, Adult Onset or Diabetes Mellitus, Ketosis-Resistant or Diabetes Mellitus, Ketosis Resistant or Ketosis-Resistant Diabetes Mellitus or Diabetes Mellitus, Non Insulin Dependent or Diabetes Mellitus, Non-Insulin-Dependent or Non-Insulin-Dependent Diabetes Mellitus or Diabetes Mellitus, Stable or Stable Diabetes Mellitus or Diabetes Mellitus, Type II or NIDDM or Diabetes Mellitus, Noninsulin Dependent or Diabetes Mellitus, Maturity-Onset or Diabetes Mellitus, Maturity Onset or Maturity-Onset Diabetes Mellitus or Maturity Onset Diabetes Mellitus or MODY or Diabetes Mellitus, Slow-Onset or Diabetes Mellitus, Slow Onset or Slow- Onset Diabetes Mellitus or Type 2 Diabetes Mellitus or Noninsulin-Dependent Diabetes Mellitus or Noninsulin Dependent Diabetes Mellitus or Maturity-Onset Diabetes or Diabetes, Maturity-Onset or Maturity Onset Diabetes or Type 2 Diabetes or Diabetes, Type 2 or Diabetes Mellitus, Noninsulin-Dependent
Outcome indicator	Continuous Glucose Monitoring [Mesh] or Glucose Monitoring, Continuous or Monitoring, Continuous Glucose or Monitorings, Continuous Glucose or Continuous Glucose Monitoring Device or CGM Device or CGM Devices or Device, CGM or Devices, CGM
Research method	RCT

Research comparison: A non-exercise control condition was required for comparison with the exercise conditions. Both randomized and non-randomized comparisons (e.g., before-andafter studies) were eligible, as were trials employing a parallel or cross-over design. However, studies comparing the combined use of exercise and dietary interventions with a control condition that did not receive a dietary intervention were deemed ineligible.

Measurement results: The study required data collected using CGM devices over a 24-hour period under both exercise and control conditions. The primary outcome measure was the mean 24-hour blood glucose level, while the secondary outcome measure was glycosylated hemoglobin (HbA1c).

### 2.3 Data extraction

Two researchers independently extracted relevant data from the articles:

- 1. Basic article data, including the first author and the year of publication.
- 2. Participant data, including age, gender, subject population, sample size, and BMI.
- 3. Exercise intervention details, including exercise period, exercise intensity, exercise frequency, and exercise duration.
- 4. Outcome indicators, including 24-hour mean blood glucose measured by CGM and HbA1c.

### 2.4 Quality evaluation

The quality of the included studies was assessed using Review Manager 5.4, following the guidelines of the Cochrane Handbook version 5.1. The assessment criteria included random allocation methods, allocation concealment, blinding, data outcome integrity, selective reporting, and other potential sources of bias. Studies were classified as low risk if they complied with these standards, high risk if they did not comply, and medium risk if there was no information provided, with the reason for this classification noted. Two researchers conducted the quality evaluation together. In the event of a disagreement, a third researcher was involved in a joint discussion to reach a consensus.

### 2.5 Data analysis

Review Manager 5.4 was used to pool effect sizes and assess publication bias. The outcome indicators included in the study were continuous variables, so the effect sizes were expressed as the mean  $\pm$  standard deviation. Heterogeneity between groups was measured using the I<sup>2</sup> statistic. If I<sup>2</sup> was less than 50%, indicating no significant statistical heterogeneity, a fixed-effect model was used for the analysis. If I<sup>2</sup> was 50% or higher, a random-effects model was applied. Funnel plots were used to evaluate the risk of bias, and sensitivity analyses were conducted to assess the robustness of the results.

### **3** Results

### 3.1 Search results

A total of 1.034 articles were retrieved: 165 from the PubMed database, 448 from the Web of Science database, 50 from the Embase database, 364 from the Cochrane database, and 7 from the EBSCO database. After reviewing the titles, abstracts, and full texts, 1,021 articles were excluded. Ultimately, 13 articles were selected for the meta-analysis. The screening process is illustrated in the figure below (see Figure 1).

## 3.2 Inclusion of the basic characteristics of the article

Study participants: A total of 626 adult participants with T2DM (30% female) were included in the study. Their age was

#### TABLE 2 Article information extraction table.

Source of literature	Subject population	Total sample size	Gender	Age	Exercise period	Exercise frequency (times/weeks)	Exercise intensity	Exercise Time (mins)	BMI (kg/m²)
Winding et al. (2018)	T2DM patients	19	Male, Female	58 ± 8	11 weeks	3	50% of Wpeak	40	28.0 ± 3.5
Winding et al. (2018)	T2DM patients	20	Male, Female	54 ± 6	11 weeks	3	95% Wpeak	20	28.0 ± 3.5
Karstoft et al. (2013)	T2DM patients	20	Male, Female	60.8 ± 2.2	4 months	5	55% of the peak energy- expenditure rate	60	29.7 ± 1.9
Karstoft et al. (2013)	T2DM patients	20	Male, Female	57.5 ± 2.4	4 months	5	70% of the peak energy- expenditure rate	60	29.7 ± 1.9
Yang et al. (2024)	T2DM patients	44	Male, Female	40.5 ± 4.78	3 months	3	50%-75% VO2 max	30-60	25.48 ± 3.75
Marcotte-Chénard et al. (2024)	T2DM patients	28	Female	69.9 ± 4.3	One day	1	90% HR max	38	33.2 ± 5.6
Marcotte-Chénard et al. (2024)	T2DM patients	28	Female	69.9 ± 4.4	One day	1	90% of HRmax	35	33.2 ± 5.6
Munan et al. (2020)	T2DM patients	25	Male, Female	65 ± 9.0	12 days	7	99 $\pm$ 18 heart rate (beats/min)	50	27.2 ± 3.5
Munan et al. (2020)	T2DM patients	26	Male, Female	65 ± 9.0	12 days	7	106 ± 17 heart rate (beats/min)	50	27.2 ± 3.5
Munan et al. (2020)	T2DM patients	25	Male, Female	65 ± 9.0	12 days	7	106 ± 19 heart rate (beats/min)	50	27.2 ± 3.5
Rees et al. (2019)	T2DM patients	63	Male, Female	64 ± 8	One day	1	65% ± 9% of HRmax	50	30.5 ± 6.5
Metcalfe et al. (2018)	T2DM patients	22	Male	52 ± 6	One day	1	50% of Wmax	30	29.1 ± 3.7
Metcalfe et al. (2018)	T2DM patients	22	Male	52 ± 6	One day	1	90HRmax	25	29.1 ± 3.7
Metcalfe et al. (2018)	T2DM patients	22	Male	52 ± 6	One day	1	91% ± 3% of HRmax	10	29.1 ± 3.7
Karstoft et al. (2017)	T2DM patients	28	Male, Female	65 ± 2	2 weeks	5	75.6% ± 2.5% of VO2peak	60	>18 kg/m <sup>2</sup> but <40 kg/m <sup>2</sup>
Karstoft et al. (2017)	T2DM patients	28	Male, Female	65 ± 2	2 weeks	5	90.0% ± 3.6% VO2peak	60	>18 kg/m <sup>2</sup> but <40 kg/m <sup>2</sup>
Myette-Côté et al. (2016)	T2DM patients	20	Male, Female	59.0 ± 9.6	One day	1	85% of VT (Ventilatory Threshold)	50	29.5 ± 4.7
Haxhi et al. (2016)	T2DM patients	18	Male	58.2 ± 6.6	One day	1	50% of heart rate reserve	40	30.2 ± 3.1

Frontiers in Physiology

(Continued on following page)

TABLE 2 (Continued) Article information extraction table.	icle information extract	tion table.							
Source of literature	Subject population	Total sample size	Gender	Age	Exercise period	Exercise frequency (times/weeks)	Exercise intensity	Exercise Time (mins)	BMI (kg/m²)
Haxhi et al. (2016)	T2DM patients	18	Male	58.2 ± 6.6	One day	1	50% of heart rate reserve	20	$30.2 \pm 3.1$
Oberlin et al. (2014)	T2DM patients	18	Male, Female	$60.3 \pm 1.0$	One day	1	60%-75% of heart rate reserve	60	$36.0 \pm 1.1$
van Dijk et al. (2012)	T2DM patients	60	Male	$60 \pm 1$	2 days	1	50% maximal workload capacity	60	<b>30.4 ± 0.7</b>
van Dijk et al. (2012)	T2DM patients	60	Male	$60 \pm 1$	One day	7	50% maximal workload capacity	30	$30.4 \pm 0.7$
Manders et al. (2010)	T2DM patients	18	Male	$57.0 \pm 2.0$	One day	1	35% Wmax	60	$29.0 \pm 1.0$
Manders et al. (2010)	T2DM patients	18	Male	57.0 ± 2.0	One day	1	70% Wmax	30	$29.0 \pm 1.0$

59.4  $\pm$  6.4 years, and their BMI was 29.61  $\pm$  2.24 kg/m<sup>2</sup>. Exercise duration includes shorter durations associated with transient blood glucose changes, involving 1-2 days, and longer durations promoting adaptive blood glucose changes, ranging from 1 to 4 months. The frequency of exercise can range from once to seven times a week. The intensity range included peak power: 50%-95%; maximum power: 35%-70%; maximum heart rate: 65%-94%; heart rate reserve: 50%-75%; maximum oxygen uptake: 50%-93%; maximum load capacity: 50%; ventilatory threshold: 85%; maximum energy expenditure rate: 55%-70%. Exercise time ranged from 10 min to 60 min (see Table 2).


### 3.3 Assessment of study quality

The quality of the included studies was evaluated, and all studies met the random sequence generation; 13 studies met the criteria for randomization (Oberlin et al., 2014; Rees et al., 2019; Winding et al., 2018; Karstoft et al., 2013; Yang et al., 2024; Marcotte-Chénard et al., 2024; Munan et al., 2020; Metcalfe et al., 2018; Karstoft et al., 2017; Myette-Côté et al., 2016; Haxhi et al., 2016; van Dijk et al., 2012; Manders et al., 2010); and 5 articles met the allocation concealment requirement (Rees et al., 2019; Winding et al., 2018; Munan et al., 2020; Metcalfe et al., 2018; Karstoft et al., 2017). None of the included articles met the criterion for blinding of participants and personnel. One article met the requirement for blinding of outcome assessment (Karstoft et al., 2013). Furthermore, 12 articles met the criterion for incomplete outcome data (Oberlin et al., 2014; Rees et al., 2019; Winding et al., 2018; Karstoft et al., 2013; Yang et al., 2024; Marcotte-Chénard et al., 2024; Munan et al., 2020; Metcalfe et al., 2018; Karstoft et al., 2017; Myette-Côté et al., 2016; Haxhi et al., 2016; van Dijk et al., 2012); 13 articles met the criterion for selective reporting (Oberlin et al., 2014; Rees et al., 2019; Winding et al., 2018; Karstoft et al., 2013; Yang et al., 2024; Marcotte-Chénard et al., 2024; Munan et al., 2020; Metcalfe et al., 2018; Karstoft et al., 2017; Myette-Côté et al., 2016; Haxhi et al., 2016; van Dijk et al., 2012; Manders et al., 2010); and 12 articles met the criterion for other sources of bias (Oberlin et al., 2014; Winding et al., 2018; Karstoft et al., 2013; Yang et al., 2024; Marcotte-Chénard et al., 2024; Munan et al., 2020; Metcalfe et al., 2018; Karstoft et al., 2017; Myette-Côté et al., 2016; Haxhi et al., 2016; van Dijk et al., 2012; Manders et al., 2010) (Figure 2).

### 3.4 Effect size evaluation

Heterogeneity testing was performed on the included studies, and a fixed-effect model was used for meta-analysis. A total of 626 participants from 23 studies provided 24-hour mean blood glucose data. The results indicated that aerobic exercise can improve the 24-hour mean blood glucose in patients with T2DM (d = -0.65, 95% CI: -0.75 to -0.55, p < 0.05) (Figure 3).

Heterogeneity testing was performed on the included studies, and a fixed-effect model was used for meta-analysis. A total of 178 participants from 7 studies provided HbA1c data, and aerobic exercise was found to improve HbA1c in patients with T2DM (d = -0.13, 95% CI: -0.25 to -0.01, p < 0.05) (Figure 4).




### 3.5 Subgroup analysis

## 3.5.1 Effects of different periods of aerobic exercise on 24-h mean blood glucose in patients with T2DM

The aerobic exercise period was categorized into three groups: 0–7 days, 7–14 days, and more than 14 days. Fourteen studies with a total sample size of 415 provided data on 24-hour mean blood glucose for the 0–7-day aerobic exercise group. Five studies with a sample size of 132 reported data for the 7–14 days group, and four studies with a sample size of 79 provided data for the group with aerobic exercise lasting more than 14 days. As shown in Figure 5, aerobic exercise for 0–7 days significantly improved the 24-hour mean blood glucose in patients with T2DM (d = –0.75, 95% CI: –0.86 to –0.64, *p* < 0.05). Aerobic exercise for 7–14 days also led to a significant improvement (d = –0.28, 95% CI: –0.50 to –0.07, *p* < 0.05). Additionally, aerobic exercise for more than 14 days improved the 24-hour mean blood glucose (d = –0.67, 95% CI: –1.19 to –0.15, *p* < 0.05).

# 3.5.2 Effect of different intensities of aerobic exercise on 24-h mean blood glucose in patients with T2DM

Aerobic exercise intensity was categorized into three groups: low-intensity, moderate-intensity, and high-intensity. Four studies with a total sample size of 94 in the low-intensity aerobic exercise group provided 24-hour mean blood glucose data; 13 studies with a sample size of 390 in the moderate-intensity aerobic exercise group provided 24-hour mean blood glucose data; and 6 studies with a sample size of 142 in the high-intensity aerobic exercise group provided 24-hour mean blood glucose data. As shown in Figure 6, low-intensity aerobic exercise cannot improve the 24hour mean blood glucose of patients with T2DM (d = -0.24, 95% CI: -0.54 to 0.05, p < 0.05). Moderate-intensity aerobic exercise can improve the 24-hour mean blood glucose of patients with T2DM (d = -0.71, 95% CI: -0.81 to -0.60, p < 0.05). High-intensity aerobic exercise can improve the 24-hour mean blood glucose of patients with T2DM (d = -0.60, 95% CI: -0.98 to -0.22, p < 0.05).



		rimen			ontrol			Mean Difference	Mean Difference
tudy or Subgroup	Mean			Mean			Weight	IV, Fixed, 95% Cl	IV, Fixed, 95% Cl
. Marcotte-Chénard 2024(1)	7.82		14	8.88	1.5	14	1.1%	-1.06 [-2.01, -0.11]	
. Marcotte-Chénard 2024(2)	8.13	1.75	14	8.88	1.5	14	0.6%	-0.75 [-1.96, 0.46]	
. J. Oberlin 2014	5.98	0.49	9	6.62		9	2.9%	-0.64 [-1.21, -0.07]	
. Myette-Côté 2016	7	1.4	10	7.2	1.3	10	0.7%	-0.20 [-1.38, 0.98]	
Haxhi 2016(1)	7.21	0.96	9	7.29	1.15	9	1.0%	-0.08 [-1.06, 0.90]	
Haxhi 2016(2)	7.18	1.58	9	7.29	1.15	9	0.6%	-0.11 [-1.39, 1.17]	
L. Rees 2019	7.4	1.5	37	7.3	1.4	26	1.8%	0.10 [-0.62, 0.82]	
W. van Dijk 2012(1)	8.3	0.3	30	9.1	0.4	30	29.5%	-0.80 [-0.98, -0.62]	
W. van Dijk 2012(2)	8.3	0.3	30	9.1	0.4	30	29.5%	-0.80 [-0.98, -0.62]	
. Karstoft 2013(1)	8.1	0.8	12	8.3	1.1	8	1.2%	-0.20 [-1.09, 0.69]	
. Karstoft 2013(2)	7.5	0.4	12	8.3	1.1	8	1.5%	-0.80 [-1.60, -0.00]	
Karstoft 2017(1)	7.5	0.5	14	8.1	0.6	14	5.6%	-0.60 [-1.01, -0.19]	
Karstoft 2017(2)	7.7	0.5	14	8.1	0.6	14	5.6%	-0.40 [-0.81, 0.01]	
. M. Winding 2018(1)	7.6	1.3	12	8.8	1.7	7	0.4%	-1.20 [-2.66, 0.26]	
. M. Winding 2018(2)	7.8	1.6	13	8.8	1.7	7	0.4%	-1.00 [-2.53, 0.53]	
. Munan 2020(1)	7.5	0.7	13	7.5	0.6	12	3.6%	0.00 [-0.51, 0.51]	
. Munan 2020(2)	7.3	0.9	14	7.5	0.6	12	2.8%	-0.20 [-0.78, 0.38]	
. Munan 2020(3)	7.6	0.8	13	7.5	0.6	12	3.1%	0.10 [-0.45, 0.65]	<del></del>
. J. Manders 2010(1)	7.8	0.9	9	9.4	0.8	9	1.5%	-1.60 [-2.39, -0.81]	
. J. Manders 2010(2)	8.7	0.7	9	9.4	0.8	9	2.0%	-0.70 [-1.39, -0.01]	
. S. Metcalfe 2018(1)	7.74	1.1	11	8.11	1.05	11	1.2%	-0.37 [-1.27, 0.53]	
. S. Metcalfe 2018(2)	7.74	0.59	11	8.11	1.05	11	1.9%	-0.37 [-1.08, 0.34]	
. S. Metcalfe 2018(3)	7.53	0.87	11	8.11	1.05	11	1.5%	-0.58 [-1.39, 0.23]	
otal (95% CI)			330			296	100.0%	-0.65 [-0.75, -0.55]	•
eterogeneity: Chi <sup>2</sup> = 38.45, df	= 22 (P =	= 0.02)	$ ^{2} = 43$	3%				-	
est for overall effect: Z = 13.07									-2 -1 0 1 2
									Favours [experimental] Favours [control]
IRE 3									

# 3.5.3 Effect of different frequencies of aerobic exercise on 24-h mean blood glucose in patients with T2DM

The frequency of aerobic exercise was categorized into three groups: once per week, 2–4 times per week, and 5–7 times per week. Thirteen studies with a total sample size of 355 provided data on 24-hour mean blood glucose for aerobic exercise performed once a week; three studies with a sample size of 99 provided data for exercise 2–4 times per week; and seven studies with a sample size of 172 provided data for exercise 5–7 times per week. As shown in Figure 7, aerobic exercise performed once a week significantly improved the 24-hour mean blood glucose levels in patients with T2DM (d = -0.71, 95% CI: -0.86 to -0.57, p < 0.05). Aerobic exercise performed 2-4 times a week also showed a significant improvement (d = -0.81, 95% CI: -0.98 to -0.63, p < 0.05). The group of

aerobic exercises performed 5–7 times a week improved the 24-hour mean blood glucose in patients with T2DM (d = -0.31, 95% CI: -0.51 to -0.11, p < 0.05).

# 3.5.4 Effect of different durations of each aerobic exercise on 24-hour mean blood glucose in patients with T2DM

The duration of aerobic exercise sessions was categorized into three groups: 0–20 min per session, 20–40 min per session, and 40–60 min per session. For the 20–40 min group, 8 studies provided data from a sample size of 215, and for the 40–60 min group, 12 studies provided data from a sample size of 351. As shown in Figure 8, aerobic exercise of 0–20 min per session did not significantly improve the 24-hour mean blood glucose levels in patients with T2DM (d = -0.54, 95% CI: -1.16 to 0.08, p < 0.05). In contrast, aerobic exercise performed for

	Expe	rimen	tal	Co	ntro	Ľ.		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
H. Yang 2024	5.9	0.4	22	6.7	1	22	7.0%	-0.80 [-1.25, -0.35]	
<. Karstoft 2013(1)	6.6	0.3	12	6.8	0.3	8	19.8%	-0.20 [-0.47, 0.07]	
<. Karstoft 2013(2)	6.8	0.3	12	6.8	0.3	8	19.8%	0.00 [-0.27, 0.27]	
<.Karstoft 2017(1)	6.6	0.4	14	6.6	0.3	14	20.8%	0.00 [-0.26, 0.26]	
<.Karstoft 2017(2)	6.5	0.3	14	6.6	0.3	14	28.8%	-0.10 [-0.32, 0.12]	
<. M. Winding 2018(1)	6.9	0.8	12	6.9	1	7	1.9%	0.00 [-0.87, 0.87]	
<. M. Winding 2018(2)	6.7	0.8	12	6.9	1	7	1.9%	-0.20 [-1.07, 0.67]	
otal (95% CI)			98			80	100.0%	-0.13 [-0.25, -0.01]	•
Heterogeneity: Chi <sup>2</sup> = 10	.80, df = I	6 (P =	0.09);	<sup>2</sup> = 44%				-	
est for overall effect: Z :	= 2.11 (P	= 0.03	3)						-1 -0.5 0 0.5 1
									Favours [experimental] Favours [control]

FIGURE 4

Forest plot showing the effect of aerobic exercise on HbA1c in patients with T2DM.

	10000000	rimen			ontrol			Mean Difference	Mean Difference
tudy or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% Cl	IV, Fixed, 95% Cl
.1.1 0-7 days									
. Marcotte-Chénard 2024(1)		1.01	14	8.88	1.5	14		-1.06 [-2.01, -0.11]	
. Marcotte-Chénard 2024(2)		1.75	14	8.88	1.5	14	0.6%	-0.75 [-1.96, 0.46]	
). J. Oberlin 2014		0.49	9		0.73	9	2.9%		
. Myette-Côté 2016	7	1.4	10	7.2	1.3	10	0.7%	-0.20 [-1.38, 0.98]	
. Haxhi 2016(1)	7.21	0.96	9	7.29	1.15	9	1.0%	-0.08 [-1.06, 0.90]	
. Haxhi 2016(2)	7.18	1.58	9	7.29	1.15	9	0.6%	-0.11 [-1.39, 1.17]	
. L. Rees 2019	7.4	1.5	37	7.3	1.4	26	1.8%	0.10 [-0.62, 0.82]	
. W. van Dijk 2012(1)	8.3	0.3	30	9.1	0.4	30	29.5%	-0.80 [-0.98, -0.62]	
. W. van Dijk 2012(2)	8.3	0.3	30	9.1	0.4	30	29.5%	-0.80 [-0.98, -0.62]	
R. J. Manders 2010(1)	7.8	0.9	9	9.4	0.8	9	1.5%	-1.60 [-2.39, -0.81]	
R. J. Manders 2010(2)	8.7	0.7	9	9.4	0.8	9	2.0%	-0.70 [-1.39, -0.01]	
R. S. Metcalfe 2018(1)	7.74	1.1	11	8.11	1.05	11	1.2%	-0.37 [-1.27, 0.53]	
R. S. Metcalfe 2018(2)	7.74	0.59	11		1.05	11	1.9%	-0.37 [-1.08, 0.34]	
R. S. Metcalfe 2018(3)		0.87	11		1.05	11	1.5%	-0.58 [-1.39, 0.23]	
ubtotal (95% CI)			213			202		0.75 [-0.86, -0.64]	♦
leterogeneity: Chi <sup>2</sup> = 16.51, df	= 13 (P =	= 0.221	: <b>I</b> ₹ = 21	%					
est for overall effect: Z = 13.11									
.1.2 7-14 days									
(Karstoft 2017(1)	7.5	0.5	14	8.1	0.6	14	5.6%	-0.60 [-1.01, -0.19]	
(.Karstoft 2017(2)	7.7	0.5	14	8.1	0.6	14	5.6%	-0.40 [-0.81, 0.01]	
1. Munan 2020(1)	7.5	0.7	13	7.5	0.6	12	3.6%	0.00 [-0.51, 0.51]	
1. Munan 2020(2)	7.3	0.9	14	7.5	0.6	12	2.8%	-0.20 [-0.78, 0.38]	
1. Munan 2020(3)	7.6	0.8	13	7.5	0.6	12	3.1%	0.10 [-0.45, 0.65]	
Subtotal (95% CI)	7.0	0.0	68	7.5	0.0	64	20.8%		•
leterogeneity: Chi² = 5.73, df =	4 /P = 0	223-12				01	20.070	-0.20 [-0.00, -0.01]	•
est for overall effect: Z = 2.60		<i>.</i> .	- 30 %						
estion overall ellect. 2 = 2.00	(1 - 0.00	3)							
.1.3 >14 days									
(. Karstoft 2013(1)	8.1	0.8	12	8.3	1.1	8	1.2%	-0.20 [-1.09, 0.69]	
(. Karstoft 2013(2)	7.5	0.4	12	8.3	1.1	8		-0.80 [-1.60, -0.00]	
(. M. Winding 2018(1)	7.6	1.3	12	8.8	1.7	7	0.4%		
(. M. Winding 2018(2)	7.8	1.6	13	8.8	1.7	7	0.4%	-1.00 [-2.53, 0.53]	
Subtotal (95% CI)	1.0	1.0	49	0.0	1.1	30		-0.67 [-1.19, -0.15]	
leterogeneity: Chi² = 1.87, df =	3 (P - 0	60\-13					0.070		
est for overall effect: Z = 2.54			- 0 70						
stron over all effect. $z = 2.34$	() = 0.01	/							
otal (95% CI)			330			296	100.0%	-0.65 [-0.75, -0.55]	•
leterogeneity: Chi² = 38.45, df	- 22 (P -	- 0 0 21		206		200			• · ·
est for overall effect: Z = 13.07				1.70					-2 -1 0 1
'est for subgroup differences:				- 0.000	101 17-	. 06 10			Favours [experimental] Favours [control]
estion subgroup dilierences:	CUL= 1	4.34, Q	i≓ z (P	- 0.000	19), 14 =	- 60.1%	D		
JRE 5									

20–40 min per session significantly improved the 24-h mean blood glucose (d = -0.75, 95% CI: -0.91 to -0.59, p < 0.05). Aerobic exercise for 40–60 min per session improved the 24-h average blood glucose in patients with T2DM (d = -0.59, 95% CI: -0.71 to -0.46, p < 0.05).

# 3.5.5 Effects of aerobic exercise on 24-hour mean blood glucose in patients with different BMIs and T2DM

Participants' BMIs were divided into three groups: <29 kg/m<sup>2</sup>, 29–30 kg/m<sup>2</sup>, and >30 kg/m<sup>2</sup>. For the group with BMI <29 kg/m<sup>2</sup>,

1.3.1 for intensity         M. Munan 2020(1)       7.5       0.7       13       7.5       0.6       12       3.6%       0.00 [-0.51, 0.51]         M. Munan 2020(2)       7.3       0.9       14       7.5       0.6       12       2.8%       -0.20 [-0.78, 0.38]         M. Munan 2020(3)       7.6       0.8       13       7.5       0.6       12       3.1%       0.10 [-0.45, 0.65]         S.J. Manders 2010(1)       7.8       0.9       9       9.4       0.8       9       1.5%       -1.60 [-2.39, -0.81]         Subtotal (95% CI)       49       45       11.1%       -0.24 [-0.54, 0.05]       -         Heterogeneity: ChiP = 13.81, df = 3 (P = 0.003); P = 78%       Festor overall effect Z = 1.63 (P = 0.10)       - <t< th=""><th>Study or Subgroup</th><th>Mean</th><th>rimen</th><th></th><th></th><th>ontrol</th><th>Total</th><th>Mojabt</th><th>Mean Difference IV, Fixed, 95% Cl</th><th>Mean Difference IV, Fixed, 95% Cl</th></t<>	Study or Subgroup	Mean	rimen			ontrol	Total	Mojabt	Mean Difference IV, Fixed, 95% Cl	Mean Difference IV, Fixed, 95% Cl
4. Munan 2020(1)       7.5       0.7       13       7.5       0.6       12       3.6%       0.00 [-0.51, 0.51]         M. Munan 2020(2)       7.3       0.9       14       7.5       0.6       12       2.8%       -0.20 [-0.76, 0.36]         M. Munan 2020(3)       7.6       0.8       13       7.5       0.6       12       2.8%       -0.20 [-0.76, 0.36]         S.J. Manders 2010(1)       7.8       0.9       9       9.4       0.8       9       1.5%       -1.60 [-2.39, -0.81]         Jubtotal (95% CI)       49       45       11.1%       -0.24 [-0.54, 0.05]         Heterogeneity: ChF=13.81, df=3 (P = 0.003); P= 78%       Feator overall effect Z = 1.63 (P = 0.10)         S.3.2 moderate intensity       0.3       0.4       0.729       1.15       9       0.0%       -0.01 [-1.38, 0.98]         J. Haxhi 2016(2)       7.18       1.58       7.29       1.15       9       0.6%       -0.01 [-1.39, 0.98]       -         J. W van Dijk 2012(2)       8.3       0.3       30       9.1       0.4       30       295%       -0.80 [-1.60, -0.62]       +       +       +       +       +       +       +       +       +       +       +       +       + <td< th=""><th></th><th>mean</th><th>30</th><th>TUtal</th><th>mean</th><th>30</th><th>rotal</th><th>weight</th><th>iv, rikeu, 95% Cl</th><th>IV, FIXEU, 95% CI</th></td<>		mean	30	TUtal	mean	30	rotal	weight	iv, rikeu, 95% Cl	IV, FIXEU, 95% CI
M. Munan 2020(2)       7.3       0.9       1.4       7.5       0.6       1.2       2.8%       -0.20 [-0.76, 0.38]         M. Munan 2020(3)       7.6       0.8       1.3       7.5       0.6       1.2       3.1%       0.10 [-0.45, 0.65]         S. Manders 2010(1)       7.8       0.9       9       4.8       9       1.5%       -1.60 [-2.39, -0.81]         Sintotai (95% CI)       49       4.8       9       1.5%       -1.60 [-2.54, 0.05]         Heterogenetic, ChF = 1.381, df = 3 (P = 0.003); P = 78%       Fest for overall effect Z = 1.53 (P = 0.10)       Fest for overall effect Z = 1.53 (P = 0.10)         K.32 moderate intensity       0.10 [-0.64, 0.85]       0.058 [-1.06, 0.96]       0.73       9       2.9%       -0.64 [-1.21, -0.07]         M.42 to 156(1)       7.14       1.6       9       7.29       1.15       9       1.0%       -0.08 [-1.08, 0.90]         J. Hashi 2016(2)       7.8       1.5       7.7.3       1.4       26       1.8%       0.10 [-0.62, 0.82]       +         J. W van Dijk 2012(2)       8.3       0.3       30       9.1       1.4       30       29.5%       -0.80 [-0.89, -0.62]       +         J. W van Dijk 2012(1)       7.5       0.4       1.8       1.8	-	7.5	07	10	75	0.6	10	2.600	0.001051.0511	
M. Munan 2020(3)       7.6       0.8       13       7.5       0.6       12       3.1%       0.10 [0.4 (0.6 c)]         R. J. Manders 2010(1)       7.8       0.9       9       4.08       9       1.5%       -1.60 [2.39,-0.61]         Munders 2010(1)       7.8       0.9       9.4       0.8       9       1.5%       -0.24 [.0.54, 0.05]         Heterogeneity: ChF = 1.381, df = 3 (P = 0.003); P = 78%       Fest for overall effect Z = 1.63 (P = 0.003); P = 78%       Fest for overall effect Z = 1.63 (P = 0.003); P = 78%         Fest for overall effect Z = 1.63 (P = 0.003); P = 78%       Fest for overall effect Z = 1.63 (P = 0.003); P = 78%         Fest for overall effect Z = 1.63 (P = 0.003); P = 78%       Fest for overall effect Z = 1.63 (P = 0.003); P = 78%         Label 2016       7       1.4       10       7.2       1.3       9       0.64 [-1.21, -0.07]         J. Ober fin 2014       5.98       0.49       9       6.62       0.73       9       2.9%       -0.64 [-1.21, -0.07]         J. Aber 2016       7.14       1.5       37       7.3       1.4       26       1.8%       0.01 [.0.6, 0.60]         J. Ward Dijk 2012(2)       8.3       0.3       30       9.1       0.4       30       29.5%       -0.00 [.0.80]         Karastot 2017(1)										
3. J. Manders 2010(1)       7.8       0.9       9       4.0       8       9       1.5%       -1.60 [ $\pm$ 2.39, -0.61]         Subtotal (95% CI)       49       45       11.1%       -0.24 [ $\pm$ 0.54, 0.05]         Fest for overall effect: Z = 1.63 (P = 0.003); P = 78%         Fest for overall effect: Z = 1.63 (P = 0.003); P = 78%         Fest for overall effect: Z = 1.63 (P = 0.003); P = 78%         Fest for overall effect: Z = 1.63 (P = 0.003); P = 78%         Fest for overall effect: Z = 1.63 (P = 0.003); P = 78%         Fest for overall effect: Z = 1.63 (P = 0.003); P = 78%         Fest for overall effect: Z = 1.63 (P = 0.003); P = 78%         Fest for overall effect: Z = 1.63 (P = 0.003); P = 78%         Fest for overall effect: Z = 1.63 (P = 0.003); P = 78%         Fest for overall effect: Z = 1.63 (P = 0.003); P = 78%         Fest for overall effect: Z = 1.63 (P = 0.02); P = 1.15         Fest for overall effect: Z = 1.01 (P = 0.02)         For overall effect: Z = 12.92 (P = 1.01         Fest for overall effect: Z = 12.92 (P < 0.00001)										
Subtotal (95% C) 49 45 11.1% $-0.24 [-0.54, 0.05]$ Heterogeneity. Ch <sup>P</sup> = 13.81, df = 3 (P = 0.003); P = 78% Fest for overall effect Z = 1.63 (P = 0.10) <b>1.3.2 moderate intensity</b> D. J. Oberlin 2014 5.98 0.49 9 6.62 0.73 9 2.9% $-0.64 [-1.21, -0.07]$ E. Myethe-Côté 2016 7 1.4 10 7.2 1.3 10 0.7% $-0.20 [-1.38, 0.98]$ D. Haxhi 2016(1) 7.21 0.86 9 7.29 1.15 9 0.6% $-0.11 [-1.39, 1.17]$ L. Rees 2019 7.4 1.5 37 7.3 1.4 26 1.8% $0.10 [-0.52, 0.82]$ D. Haxhi 2016(2) 7.18 1.58 9 7.29 1.15 9 0.6% $-0.11 [-1.39, 1.17]$ L. Rees 2019 7.4 1.5 37 7.3 1.4 26 1.8% $0.02 [-5.6, 0.05]$ , 0.80 [-0.98, -0.62] W. Van Dijk 2012(2) 8.3 0.3 30 9.1 0.4 30 29.5% $-0.80 [-0.98, -0.62]$ (Karstoth 2013(1) 8.1 0.8 12 8.3 1.1 8 1.2% $-0.20 [-1.60, 0.00]$ (Karstoth 2013(2) 7.5 0.5 14 8.1 0.6 14 5.6% $-0.60 [-1.61, -0.10]$ (Karstoth 2017(2) 7.7 0.5 14 8.1 0.6 14 5.6% $-0.60 [-1.61, -0.10]$ (Karstoth 2017(2) 7.7 0.5 14 8.1 0.6 14 5.6% $-0.75 [-1.96, 0.01]$ (Karstoth 2017(2) 8.7 0.7 9 9.4 0.8 9 2.0% $-0.70 [-1.39, -0.01]$ Hutorial g5% C1) 207 183 82.3% $-0.71 [-0.81, -0.60]$ Heterogeneity. Ch <sup>P</sup> = 14.20, df = 12 (P = 0.29); P = 16% Fest for overall effect Z = 12.92 (P < 0.00001) <b>1.3.3 high intensity</b> A Marcotte-Chénard 2024(1) 7.82 1.01 14 8.88 1.5 14 1.1% $-1.06 [-2.01, -0.11]$ A Marcotte-Chénard 2024(2) 7.74 1.1 11 8.11 1.05 11 1.2% $-0.37 [-1.38, 0.53]$ S. Metcalfe 2018(2) 7.74 0.59 11 8.11 1.05 11 1.2% $-0.37 [-1.27, 0.53]$ S. Metcalfe 2018(2) 7.74 0.59 11 8.11 1.05 11 1.2% $-0.37 [-1.27, 0.53]$ S. Metcalfe 2018(2) 7.74 0.59 11 8.11 1.05 11 1.9% $-0.58 [-1.39, 0.23]$ <b>4.</b> Heterogeneity. Ch <sup>P</sup> = 18.8, df = 5 (P = 0.07); P = 0% Fest for overall effect Z = 3.12 (P = 0.002) <b>4.</b> Heterogeneity. Ch <sup>P</sup> = 18.8, df = 5 (P = 0.02); P = 43% Fest for overall effect Z = 13.07 (P < 0.00001)										
The set for overall effect $Z = 1.63$ (P = 0.10) <b>1.3.2 moderate intensity</b> <b>1.3.2 moderate intensity</b> <b>1.3.4 potential 2016</b> <b>1.4 set 2016</b> <b>1.5 structure intensity</b> <b>1.4 set 2016</b> <b>1.5 structure intensity</b> <b>1.4 set 2016</b> <b>1.5 structure intensity</b> <b>1.4 set 2016</b> <b>1.5 structure intensity</b> <b>1.4 set 2016</b> <b>1.6 structure intensity</b> <b>1.4 set 2016</b> <b>1.7 structure intensity</b> <b>1.4 set 2016</b> <b>1.7 structure intensity</b> <b>1.4 set 2019</b> <b>1.4 set 2013</b> <b>1.1 structure intensity</b> <b>1.4 set 2013</b> <b>1.1 structure intensity</b> <b>1.3 structure intensity</b>		7.8	0.9		9.4	0.8				
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	leterogeneity: Chi <sup>2</sup> = 13.81, df	= 3 (P =	0.003)	; <b>I</b> ² = 78	1%					
J. Oberlin 2014 5.98 0.49 9 6.62 0.73 9 2.9% $-0.64[-1.21, -0.07]$ Myette-Côté 2016 7 1.4 10 7.2 1.3 10 0.7% $-0.20[-1.38, 0.98]$ Haxhi 2016(1) 7.21 0.96 9 7.29 1.15 9 0.6% $-0.01[-1.39, 0.98]$ Haxhi 2016(2) 7.18 1.58 9 7.29 1.15 9 0.6% $-0.01[-0.62, 0.82]$ W van Dijk 2012(1) 8.3 0.3 30 9.1 0.4 30 29.5% $-0.80[-0.98, -0.62]$ W van Dijk 2012(2) 8.3 0.3 30 9.1 0.4 30 29.5% $-0.80[-0.98, -0.62]$ Karstoft 2013(1) 8.1 0.8 12 8.3 1.1 8 1.2% $-0.20[-1.90, 0.69]$ Karstoft 2013(2) 7.5 0.4 12 8.3 1.1 8 1.5% $-0.80[-1.00, -0.00]$ Karstoft 2013(2) 7.5 0.4 12 8.3 1.1 8 1.5% $-0.80[-1.00, -0.00]$ Karstoft 2013(2) 7.7 0.5 14 8.1 0.6 14 5.6% $-0.60[-1.01, -0.19]$ Karstoft 2013(2) 7.7 0.5 14 8.1 0.6 14 5.6% $-0.00[-1.81, -0.00]$ Karstoft 2013(2) 7.7 0.5 14 8.1 0.6 14 5.6% $-0.00[-1.81, -0.00]$ Karstoft 2013(2) 7.7 0.5 14 8.1 0.6 14 5.6% $-0.00[-1.81, -0.60]$ through 2018(1) 7.6 1.3 12 8.8 1.7 7 0.4% $-1.20[-2.66, 0.26]$ J. Manders 2010(2) 8.7 0.7 9 9.4 0.8 9 2.0% $-0.70[-1.39, -0.01]$ through 2018(2) 7.8 1.6 13 8.8 1.5 14 $0.6\% -0.75[-1.96, 0.46]$ M. Winding 2018(2) 7.8 1.6 13 8.8 1.7 7 0.4% $-1.00[-2.53, 0.53]$ S. Metcalfe 2018(2) 7.74 0.59 11 8.11 1.05 11 1.2% $-0.37[-1.27, 0.53]$ S. Metcalfe 2018(2) 7.74 0.59 11 8.11 1.05 11 1.2% $-0.37[-1.27, 0.53]$ S. Metcalfe 2018(2) 7.74 0.59 11 8.11 1.05 11 1.2% $-0.37[-1.27, 0.53]$ S. Metcalfe 2018(2) 7.74 0.59 11 8.11 1.05 11 1.2% $-0.37[-1.27, 0.53]$ S. Metcalfe 2018(2) 7.74 0.59 11 8.11 1.05 11 1.9% $-0.37[-1.27, 0.53]$ S. Metcalfe 2018(3) 7.53 0.87 11 8.11 1.05 11 1.9% $-0.37[-1.27, 0.53]$ S. Metcalfe 2018(3) 7.53 0.87 11 8.11 1.05 11 1.9% $-0.37[-1.27, 0.53]$ S. Metcalfe 2018(3) 7.53 0.87 11 8.11 1.05 11 1.9% $-0.37[-1.27, 0.53]$ S. Metcalfe 2018(3) 7.53 0.87 11 8.11 1.05 11 1.9% $-0.37[-1.27, 0.55]$ eterogeneity: Chi <sup>P</sup> = 1.88, df = 5 (P = 0.27); P = 0% estfor overall effect Z = 1.3.07 (P < 0.00001) Faultof 4.5% Ch - 2.6, 0.0001 Figure 4.3% Estfor overall effect Z = 1.3.07 (P < 0.00001)	est for overall effect: Z = 1.63	(P = 0.10	ŋ (							
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	3.2 moderate intensity									
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	. J. Oberlin 2014	5.98	0.49	9	6.62	0.73	9	2.9%	-0.64 [-1.210.07]	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $										
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	,									
L. Rees 2019 7.4 1.5 37 7.3 1.4 26 1.8% $0.10[0.62, 0.82]$ W. van Dijk 2012(1) 8.3 0.3 30 9.1 0.4 30 29.5% $-0.80[0.98, -0.62]$ W. van Dijk 2012(2) 8.3 0.3 30 9.1 0.4 30 29.5% $-0.80[-0.98, -0.62]$ W. van Dijk 2012(2) 8.3 0.3 30 9.1 0.4 30 29.5% $-0.80[-0.98, -0.62]$ Karstoft 2013(1) 8.1 0.8 12 8.3 1.1 8 1.2% $-0.20[1.09, 0.69]$ Karstoft 2017(1) 7.5 0.5 14 8.1 0.6 14 5.6% $-0.60[1.01, -0.19]$ Karstoft 2017(2) 7.7 0.5 14 8.1 0.6 14 5.6% $-0.40[0.81, 0.01]$ Karstoft 2017(2) 7.7 0.5 14 8.1 0.6 14 5.6% $-0.40[0.81, 0.01]$ Karstoft 2018(1) 7.6 1.3 12 8.8 1.7 7 0.4% $-1.20[2.66, 0.26]$ W. Winding 2018(1) 7.6 1.3 12 8.8 1.7 7 0.4% $-1.20[2.66, 0.26]$ W. Munding 2018(1) 7.6 1.3 12 8.8 1.7 7 0.4% $-1.00[2.53, 0.51]$ And reter ogeneity: Chi <sup>2</sup> = 14.20, df = 12 (P = 0.29); P = 16% Test for overall effect: Z = 12.92 (P < 0.00001) 3.3 high intensity Marcotte-Chénard 2024(1) 7.82 1.01 14 8.88 1.5 14 1.1% $-1.06[2.01, -0.11]$ Marcotte-Chénard 2024(2) 8.13 1.75 14 8.88 1.5 14 0.6% $-0.75[-1.96, 0.46]$ M. Winding 2018(2) 7.74 0.59 11 8.11 1.05 11 1.2% $-0.37[-1.08, 0.34]$ S. Metcalfe 2018(2) 7.74 0.59 11 8.11 1.05 11 1.5% $-0.58[-1.39, 0.23]$ Mutotal (95% CI) 74 0.59 11 8.11 1.05 11 1.5% $-0.58[-1.39, 0.23]$ Heterogeneity: Chi <sup>2</sup> = 1.88, df = 5 (P = 0.87); P = 0% Test for overall effect: Z = 3.12 (P = 0.002) otal (95% CI) 30 296 100.0% $-0.65[-0.75, -0.55]$ Heterogeneity: Chi <sup>2</sup> = 1.88, df = 5 (P = 0.87); P = 0% Test for overall effect: Z = 3.10.7 (P < 0.00001)										
L. W. van Dijk 2012(1) 8.3 0.3 30 9.1 0.4 30 29.5% -0.80 [-0.88, -0.62] J. W. van Dijk 2012(2) 8.3 0.3 30 9.1 0.4 30 29.5% -0.80 [-0.88, -0.62] J. W. van Dijk 2012(2) 8.3 0.3 30 9.1 0.4 30 29.5% -0.80 [-0.88, -0.62] C. Karstoft 2013(1) 8.1 0.8 12 8.3 1.1 8 1.2% -0.20 [-1.09, 0.69] C. Karstoft 2013(2) 7.5 0.4 12 8.3 1.1 8 1.5% -0.80 [-1.80, -0.00] C. Karstoft 2017(2) 7.5 0.5 14 8.1 0.6 14 5.6% -0.60 [-1.60, -0.01] C. Karstoft 2017(2) 7.6 1.3 12 8.8 1.7 7 0.4% -1.20 [-2.66, 0.26] R. J. Manders 2010(2) 8.7 0.7 9 9.4 0.8 9 2.0% -0.71 [-0.81, -0.60] Heterogeneity: Chi <sup>2</sup> = 14.20, df = 12 (P = 0.29); P = 16% Fest for overall effect Z = 12.92 (P < 0.00001) H. Marcotte-Chénard 2024(1) 7.82 1.01 14 8.88 1.5 14 1.1% -1.06 [-2.01, -0.11] M. Marcotte-Chénard 2024(2) 8.13 1.75 14 0.88 1.5 14 0.6% -0.75 [-1.96, 0.46] C. M. Winding 2018(2) 7.8 1.6 13 8.8 1.7 7 0.4% -1.00 [-2.51, -5.5] R. S. Metcalfe 2018(3) 7.53 0.87 11 8.11 1.05 11 1.2% -0.37 [-1.27, 0.53] R. S. Metcalfe 2018(3) 7.53 0.87 11 8.11 1.05 11 1.9% -0.37 [-1.27, 0.53] R. S. Metcalfe 2018(3) 7.53 0.87 11 8.11 1.05 11 1.9% -0.37 [-1.27, 0.53] R. S. Metcalfe 2018(3) 7.53 0.87 11 8.11 1.05 11 1.9% -0.36 [-1.39, 0.23] Subtotal (95% CI) 74 68 6.6% -0.60 [-0.98, -0.22] Heterogeneity: Chi <sup>2</sup> = 1.88, df = 5 (P = 0.87); P = 0% Fest for overall effect Z = 13.07 (P < 0.00001) Fotal (95% CI) 74 0.00001) Fotal (95% CI) 74 0.00001) Fotal (95% CI) 74 0.00001) Fator overall effect Z = 13.07 (P < 0.00001) Fator over										
I. W. van Dijk 2012(2)       8.3       0.3       30       9.1       0.4       30       29.5% $-0.80$ [ $-0.98$ , $-0.62$ ]         Karstoft 2013(1)       8.1       1.0       8       1.2       8.3       1.1       8       1.2% $-0.20$ [ $-1.09$ , $0.69$ ]         Karstoft 2013(2)       7.5       0.4       1.2       8.3       1.1       8       1.2% $-0.20$ [ $-1.09$ , $0.69$ ]         Karstoft 2017(1)       7.5       0.5       1.4       8.1       0.6       1.4       5.6% $-0.60$ [ $-1.01$ , $-0.19$ ]         Karstoft 2017(2)       7.7       0.5       1.4       8.1       0.6       1.4       5.6% $-0.40$ [ $-0.81$ , $0.01$ ]         Karstoft 2017(2)       7.7       0.5       1.4       8.1       0.6       1.4       5.6% $-0.40$ [ $-0.81$ , $0.01$ ]         Subtotat (95% CI)       207       183       82.3% $-0.71$ [ $-0.81$ , $-0.60$ ] $-0.60$ ]         Hetrogeneity: Chi <sup>P</sup> = 14.20, df = 12 (P = 0.29); P = 16%       1.0       1.4       8.88       1.5       1.4       1.1% $-0.61$ [ $-2.01$ , $-0.11$ ]         A. Marcotte-Chénard 2024(1)       7.8       1.6       13       8.8       1.7       7 $0.4\%$ $-0.00$ [ $-2.53$ , $0.53$ ]										-
C Karstoft 2013(1) 8.1 0.8 12 8.3 1.1 8 1.2% $-0.20[-1.09, 0.69]$ C Karstoft 2013(2) 7.5 0.4 12 8.3 1.1 8 1.5% $-0.80[-1.60, -0.00]$ C Karstoft 2017(1) 7.5 0.5 14 8.1 0.6 14 5.6% $-0.40[-0.81, 0.01]$ C Karstoft 2017(2) 7.7 0.5 14 8.1 0.6 14 5.6% $-0.40[-0.81, 0.01]$ C Karstoft 2017(2) 7.7 0.5 14 8.1 0.6 14 5.6% $-0.40[-0.81, 0.01]$ C Karstoft 2017(2) 7.7 0.5 14 8.1 0.6 14 5.6% $-0.40[-0.81, 0.01]$ C M. Vinding 2018(1) 7.6 1.3 12 8.8 1.7 7 0.4% $-1.20[-2.66, 0.26]$ C M. Vinding 2018(2) 8.7 0.7 9 9.4 0.8 9 2.0% $-0.70[-1.39, -0.01]$ Subtotat (95% CI) 207 183 82.3% $-0.71[-0.81, -0.60]$ Heterogeneity: Chi <sup>2</sup> = 14.20, df = 12 (P = 0.29); P = 16% Test for overall effect Z = 12.92 (P < 0.00001) A marcotte-Chénard 2024(2) 8.13 1.75 14 8.88 1.5 14 0.6% $-0.75[-1.96, 0.46]$ C M. Vinding 2018(2) 7.8 1.6 13 8.8 1.7 7 0.4% $-1.00[-2.53, 0.53]$ C. M. Vinding 2018(2) 7.8 1.6 13 8.8 1.7 7 0.4% $-0.37[-1.27, 0.53]$ R. S. Metcalfe 2018(2) 7.74 0.59 11 8.11 1.05 11 1.2% $-0.37[-1.27, 0.53]$ R. S. Metcalfe 2018(3) 7.53 0.87 11 8.11 1.05 11 1.9% $-0.37[-1.29, 0.23]$ Lattotat (95% CI) 74 0.59 11 8.11 1.05 11 1.9% $-0.68[-3.09, 0.22]$ Heterogeneity: Chi <sup>2</sup> = 1.88, df = 5 (P = 0.87); I <sup>2</sup> = 0% Test for overall effect: Z = 3.12 (P = 0.002) Total (95% CI) 74 0.59 11 8.11 1.05 11 1.5% $-0.65[-0.75, -0.55]$ Heterogeneity: Chi <sup>2</sup> = 38.45, df = 22 (P = 0.02); I <sup>2</sup> = 43% Test for overall effect: Z = 13.07 (P < 0.00001) Total (95% CI) 74 0.59 11 8.11 1.05 11 1.5% $-0.65[-0.75, -0.55]$ Heterogeneity: Chi <sup>2</sup> = 38.45, df = 22 (P = 0.02); I <sup>2</sup> = 43% Test for overall effect: Z = 13.07 (P < 0.00001) Total (95% CI) 74 0.5001 Test for overall effect: Z = 13.07 (P < 0.00001)										-
C Karstoft 2013(2) 7.5 0.4 12 8.3 1.1 8 1.5% $-0.80[-1.60, -0.00]$ C Karstoft 2017(1) 7.5 0.5 14 8.1 0.6 14 5.6% $-0.60[-1.01, -0.19]$ C Karstoft 2017(2) 7.7 0.5 14 8.1 0.6 14 5.6% $-0.40[-0.81, 0.01]$ C Karstoft 2017(2) 7.7 0.5 14 8.1 0.6 14 5.6% $-0.40[-0.81, 0.01]$ C M. Vinding 2018(1) 7.6 1.3 12 8.8 1.7 7 0.4% $-1.20[-2.66, 0.26]$ C M. Vinding 2018(2) 8.7 0.7 9 9.4 0.8 9 2.0% $-0.70[-1.39, -0.01]$ Subtotal (95% CI) 207 183 82.3% $-0.71[-0.81, -0.60]$ The terogeneity: Chi <sup>P</sup> = 14.20, df = 12 (P = 0.29); I <sup>P</sup> = 16% Test for overall effect: Z = 12.92 (P < 0.00001) <b>3.3 high intensity</b> C Marcotte-Chénard 2024(1) 7.82 1.01 14 8.88 1.5 14 0.6% $-0.75[-1.96, 0.46]$ C M. Vinding 2018(2) 7.8 1.6 13 8.8 1.7 7 0.4% $-1.00[-2.53, 0.53]$ R. S. Metcalfe 2018(2) 7.74 0.59 11 8.11 1.05 11 1.2% $-0.37[-1.27, 0.53]$ R. S. Metcalfe 2018(2) 7.74 0.59 11 8.11 1.05 11 1.2% $-0.37[-1.28, 0.23]$ Labtotal (95% CI) 74 0.59 11 8.11 1.05 11 1.5% $-0.58[-1.39, 0.23]$ Labtotal (95% CI) 74 0.59 11 8.11 1.05 11 1.5% $-0.58[-1.39, 0.23]$ Labtotal (95% CI) 74 0.59 11 8.11 1.05 11 1.5% $-0.58[-1.39, 0.23]$ Labtotal (95% CI) 74 0.59 11 8.11 1.05 11 1.5% $-0.58[-1.39, 0.23]$ Labtotal (95% CI) 74 0.59 11 8.11 1.05 11 1.5% $-0.58[-1.39, 0.23]$ Labtotal (95% CI) 74 0.59 11 8.11 1.05 11 1.5% $-0.58[-1.39, 0.23]$ Labtotal (95% CI) 74 0.59 11 8.11 1.05 11 1.5% $-0.58[-1.39, 0.23]$ Labtotal (95% CI) 74 0.59 11 8.11 1.05 11 1.5% $-0.58[-1.39, 0.23]$ Labtotal (95% CI) 74 0.59 11 8.11 1.05 11 1.5% $-0.58[-1.39, 0.23]$ Labtotal (95% CI) 74 0.59 11 8.11 1.05 11 1.5% $-0.58[-1.39, 0.23]$ Labtotal (95% CI) 74 0.59 11 8.11 1.05 11 1.5% $-0.58[-1.39, 0.23]$ Labtotal (95% CI) 74 0.59 11 8.11 1.05 11 1.5% $-0.56[-0.75, -0.55]$ Labtotal (95% CI) 74 0.59 11 8.11 1.05 11 1.5% $-0.56[-0.75, -0.55]$ Labtotal (95% CI) 74 0.59 11 8.11 1.05 11 1.5% $-0.56[-0.75, -0.55]$ Labtotal (95% CI) 74 0.59 11 8.11 1.05 11 1.5% $-0.56[-0.75, -0.55]$ Labtotal (95% CI) 74 0.59 11 8.11 1.5% $-0.56[-0.75, -0.55]$ Labtotal (95% CI) 75 0.00001										
$\begin{array}{c c c c c c c c c c c c c c c c c c c $										
$\begin{array}{c c c c c c c c c c c c c c c c c c c $										
K. M. Winding 2018(1)       7.6       1.3       12       8.8       1.7       7 $0.4\%$ $-1.20$ [-2.66, 0.26]         R. J. Manders 2010(2)       8.7       0.7       9       9.4       0.8       9       2.0% $-0.70$ [-1.39, $-0.01$ ]         Subtotal (95% CI)       207       183       82.3% $-0.71$ [-0.81, $-0.60$ ]         Heterogeneity: Chi <sup>2</sup> = 14.20, df = 12 (P = 0.29); P = 16%       Fest for overall effect: Z = 12.92 (P < 0.00001)	• •									
R. J. Manders 2010(2)       8.7       0.7       9       9.4       0.8       9       2.0%       -0.70 [±1.39, -0.01]         Subtotal (95% CI)       207       183       82.3%       -0.71 [-0.81, -0.60]         Heterogeneity: Chi <sup>2</sup> = 14.20, df = 12 (P = 0.29); $ ^{P} = 16\%$ .       .       .       .         Test for overall effect: Z = 12.92 (P < 0.00001)	• •					1000				
Subtotal (95% Cl)       207       183       82.3%       -0.71 [-0.81, -0.60]         Heterogeneity: Chi <sup>2</sup> = 14.20, df = 12 (P = 0.29); I <sup>2</sup> = 16%         Fest for overall effect: Z = 12.92 (P < 0.00001)										
$\begin{array}{c} \text{Heterogeneity: Chi^{2} = 14.20, df = 12 (P = 0.29); I^{2} = 16\% \\ \text{fest for overall effect: } Z = 12.92 (P < 0.00001) \\ \textbf{.3.3 high intensity} \\ \textbf{. Marcottle-Chénard 2024(1) } 7.82 1.01 14 8.88 1.5 14 1.1\% -1.06 [-2.01, -0.11] \\ \textbf{. Marcottle-Chénard 2024(2) } 8.13 1.75 14 8.88 1.5 14 0.6\% -0.75 [-1.96, 0.46] \\ \textbf{. M. Winding 2018(2) } 7.8 1.6 13 8.8 1.7 7 0.4\% -1.00 [-2.53, 0.53] \\ \textbf{. S. Metcalfe 2018(1) } 7.74 1.1 11 8.11 1.05 11 1.2\% -0.37 [-1.08, 0.34] \\ \textbf{. S. Metcalfe 2018(2) } 7.53 0.87 11 8.11 1.05 11 1.5\% -0.58 [-1.39, 0.23] \\ \textbf{. S. Metcalfe 2018(3) } 7.53 0.87 11 8.11 1.05 11 1.5\% -0.58 [-1.39, 0.23] \\ \textbf{. Metcalfe 2018(3) } 7.53 0.87 11 8.11 1.05 11 1.5\% -0.58 [-1.39, 0.23] \\ \textbf{. ubtotal (95% Cl) } 74 68 6.6\% -0.60 [-0.98, -0.22] \\ \textbf{. eterogeneity: Chi^{2} = 1.88, df = 5 (P = 0.87); I^{2} = 0\% \\ \textbf{. est for overall effect: } Z = 3.12 (P = 0.002) \\ \textbf{. deterogeneity: Chi^{2} = 38.45, df = 22 (P = 0.02); I^{2} = 43\% \\ \textbf{. est for overall effect: } Z = 13.07 (P < 0.00001) \\ \end{array}$		0.7	0.7		9.4	0.0	-			•
Fest for overall effect: $Z = 12.92$ (P < 0.00001)	Standingson Sectors and Sectors and Sectors	- 12 (P -	- 0.201		.06		100	02.070	an i l'aia il aigal	•
.3.3 high intensity        Marcotte-Chénard 2024(1)       7.82       1.01       14       8.88       1.5       14       1.1%       -1.06 [-2.01, -0.11]        Marcotte-Chénard 2024(2)       8.13       1.75       14       8.88       1.5       14       0.6%       -0.75 [-1.96, 0.46]        Marcotte-Chénard 2024(2)       8.13       1.75       14       8.88       1.5       14       0.6%       -0.75 [-1.96, 0.46]        Marcotte-Chénard 2018(2)       7.8       1.6       13       8.8       1.7       7       0.4%       -1.00 [-2.53, 0.53]	2 , 1	•	·	, - 10	0.0					
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	estion overall effect. Z = 12.92	: (r × 0.0	0001)							
Marcotte-Chénard 2024(2)       8.13       1.75       14       8.88       1.5       14       0.6%       -0.75       [-1.96, 0.46]         M. Winding 2018(2)       7.8       1.6       13       8.8       1.7       7       0.4%       -1.00       [-2.53, 0.53]         S. S. Metcalfe 2018(1)       7.74       1.1       11       8.11       1.05       11       1.2%       -0.37       [-1.27, 0.53]         R. S. Metcalfe 2018(2)       7.74       0.59       11       8.11       1.05       11       1.9%       -0.37       [-1.39, 0.34]         S. S. Metcalfe 2018(3)       7.53       0.87       11       8.11       1.05       11       1.5%       -0.58       [-1.39, 0.23]         Gubtotal (95% CI)       74       68       6.6%       -0.60 [-0.98, -0.22]       -       -       -       -         Heterogeneity: Chi <sup>2</sup> = 1.88, df = 5 (P = 0.87); I <sup>2</sup> = 0%       74       68       6.6%       -0.65 [-0.75, -0.55]       -	.3.3 high intensity									
K. M. Winding 2018(2)       7.8       1.6       13       8.8       1.7       7 $0.4\%$ $-1.00$ [-2.53, 0.53]         R. S. Metcalfe 2018(1)       7.74       1.1       11       8.11 $1.05$ 11 $1.2\%$ $-0.37$ [-1.27, 0.53]         R. S. Metcalfe 2018(2)       7.74 $0.59$ 11 $8.11$ $1.05$ 11 $1.9\%$ $-0.37$ [-1.27, 0.53]         R. S. Metcalfe 2018(2)       7.74 $0.59$ 11 $8.11$ $1.05$ $11$ $1.9\%$ $-0.37$ [-1.28, 0.34]         R. S. Metcalfe 2018(3)       7.53 $0.87$ 11 $8.11$ $1.05$ $11$ $1.9\%$ $-0.68$ [-1.39, 0.23]         Subtotal (95% Cl)       74       68 $6.6\%$ $-0.60$ [-0.98, $-0.22$ ] $-0.65$ [-0.75, $-0.55$ ]         Heterogeneity: Chi <sup>2</sup> = 1.88, df = 5 (P = 0.87); l <sup>2</sup> = 0%       74       68 $6.6\%$ $-0.65$ [-0.75, $-0.55$ ]         Heterogeneity: Chi <sup>2</sup> = 38.45, df = 22 (P = 0.02); l <sup>2</sup> = 43%       74 $-2$ $-1$ $-2$ $-1$ $-2$ $-1$ $-2$ $-1$ $-2$ $-1$ $-2$ $-1$ $-2$ $-1$ $-2$ $-1$ $-2$ $-1$	A. Marcotte-Chénard 2024(1)									
R. S. Metcaffe 2018(1)       7.74       1.1       11       8.11       1.05       11       1.2% $-0.37$ [-1.27, 0.53]         R. S. Metcaffe 2018(2)       7.74       0.59       11       8.11       1.05       11       1.9% $-0.37$ [-1.08, 0.34]         R. S. Metcaffe 2018(3)       7.53       0.87       11       8.11       1.05       11       1.5% $-0.58$ [-1.39, 0.23]         Subtotal (95% Cl)       74       68       6.6% $-0.60$ [-0.98, $-0.22$ ]         Heterogeneity: Chi <sup>2</sup> = 1.88, df = 5 (P = 0.87); I <sup>2</sup> = 0%       74       68       6.6% $-0.60$ [-0.98, $-0.22$ ]         Fost for overall effect: Z = 3.12 (P = 0.002)       74       68       6.6% $-0.65$ [-0.75, $-0.55$ ]         Heterogeneity: Chi <sup>2</sup> = 38.45, df = 22 (P = 0.02); I <sup>2</sup> = 43%       296       100.0% $-0.65$ [-0.75, $-0.55$ ]         Heterogeneity: Chi <sup>2</sup> = 38.45, df = 22 (P = 0.02); I <sup>2</sup> = 43%       -2       -1       0         Fest for overall effect: Z = 13.07 (P < 0.00001)	A. Marcotte-Chénard 2024(2)									
R. S. Metcalfe 2018(2)       7.74       0.59       11       8.11       1.05       11       1.9% $-0.37$ [-1.08, 0.34]         R. S. Metcalfe 2018(3)       7.53       0.87       11       8.11       1.05       11       1.5% $-0.58$ [-1.39, 0.23]         Subtotal (95% Cl)       74       68       6.6% $-0.60$ [-0.98, $-0.22$ ]         Heterogeneity: Chi <sup>2</sup> = 1.88, df = 5 (P = 0.87); I <sup>2</sup> = 0%       74       68       6.6% $-0.60$ [-0.98, $-0.22$ ]         Fost for overall effect: Z = 3.12 (P = 0.002)       330       296       100.0% $-0.65$ [-0.75, $-0.55$ ]         Heterogeneity: Chi <sup>2</sup> = 38.45, df = 22 (P = 0.02); I <sup>2</sup> = 43% $-2$ $-1$ $0$ Fest for overall effect: Z = 13.07 (P < 0.00001)	<. M. Winding 2018(2)	7.8	1.6	13			7	0.4%		
R. S. Metcalfe 2018(3) 7.53 0.87 11 8.11 1.05 11 1.5% -0.58 [-1.39, 0.23] Subtotal (95% Cl) 74 68 6.6% -0.60 [-0.98, -0.22] Heterogeneity: Chi <sup>2</sup> = 1.88, df = 5 (P = 0.87); I <sup>2</sup> = 0% Fest for overall effect: Z = 3.12 (P = 0.002) Fotal (95% Cl) 330 296 100.0% -0.65 [-0.75, -0.55] Heterogeneity: Chi <sup>2</sup> = 38.45, df = 22 (P = 0.02); I <sup>2</sup> = 43% Fest for overall effect: Z = 13.07 (P < 0.00001) Fest for overall effect: Z = 13.07 (P < 0.00001)	R. S. Metcalfe 2018(1)	7.74	1.1	11	8.11	1.05	11	1.2%	-0.37 [-1.27, 0.53]	
Subtotal (95% Cl)       74       68       6.6%       -0.60 [-0.98, -0.22]         Heterogeneity: Chi <sup>2</sup> = 1.88, df = 5 (P = 0.87); I <sup>2</sup> = 0%       Fest for overall effect: Z = 3.12 (P = 0.002)       74       68       6.6%       -0.60 [-0.98, -0.22]         Fotal (95% Cl)       330       296       100.0%       -0.65 [-0.75, -0.55]       -2       -1       0       1         Heterogeneity: Chi <sup>2</sup> = 38.45, df = 22 (P = 0.02); I <sup>2</sup> = 43%       -2       -1       0       1         Fest for overall effect: Z = 13.07 (P < 0.00001)	R. S. Metcalfe 2018(2)							1.9%		
Heterogeneitly: Chi <sup>2</sup> = 1.88, df = 5 (P = 0.87); i <sup>2</sup> = 0%         Fest for overall effect: Z = 3.12 (P = 0.002)         Fotal (95% CI)       330         296       100.0%       -0.65 [-0.75, -0.55]         Heterogeneitly: Chi <sup>2</sup> = 38.45, df = 22 (P = 0.02); i <sup>2</sup> = 43%       -2       -1       0         Fest for overall effect: Z = 13.07 (P < 0.00001)	R. S. Metcalfe 2018(3)	7.53	0.87		8.11	1.05				
Fest for overall effect: Z = 3.12 (P = 0.002)         Fotal (95% CI)       330       296       100.0%       -0.65 [-0.75, -0.55]         Heterogeneity: Chi² = 38.45, df = 22 (P = 0.02); I² = 43%       -2       -1       0       1         Fest for overall effect: Z = 13.07 (P < 0.00001)	Subtotal (95% CI)			74			68	6.6%	-0.60 [-0.98, -0.22]	-
State         330         296         100.0%         -0.65         [-0.75, -0.55]           Heterogeneity: Chi <sup>2</sup> = 38.45, df = 22 (P = 0.02); I <sup>2</sup> = 43%         -2         -1         0         1           Fest for overall effect: Z = 13.07 (P < 0.00001)				= 0%						
Heterogeneity: Chi <sup>2</sup> = 38.45, df = 22 (P = 0.02); I <sup>2</sup> = 43%         -1         -1         -1           Test for overall effect: Z = 13.07 (P < 0.00001)	fest for overall effect: Z = 3.12	(P = 0.00	12)							
Fest for overall effect: Z = 13.07 (P < 0.00001) -2 -1 U 1 Favours [experimental] - Favours [contri	Total (95% CI)			330			296	<b>100.0</b> %	-0.65 [-0.75, -0.55]	•
Fest for overall effect: Z = 13.07 (P < 0.00001) Eavours (control of the second s	Heterogeneity: Chi <sup>2</sup> = 38.45, df	= 22 (P =	= 0.02)	; <b>I</b> ² = 43	1%				-	
Test for subgroup differences: Chiž = 9.56 df = 2.7P = 0.01) iz = 76.60.	Test for overall effect: Z = 13.07	r (P < 0.0	0001)							2 1 0 1
estion subgroup unierences. Chi = 6.56, ul = 2 (F = 0.01), T = 76.6%	Test for subgroup differences:	Chi <sup>2</sup> = 8.	56, df:	= 2 (P =	0.01),	I <sup>2</sup> = 76.	6%			ravours (experimental) - ravours (conti

5 studies provided 24-hour mean blood glucose data from a sample size of 115. For the 29–30 kg/m<sup>2</sup> group, 8 studies provided 24-hour mean blood glucose data from a sample size of 162. For the BMI >30 kg/m<sup>2</sup> group, 8 studies provided 24-hour blood glucose data from a sample size of 293. As shown in Figure 9, aerobic exercise did not significantly improve the 24-hour mean blood glucose in patients with T2DM in the BMI <29 group (d = -0.11, 95% CI: -0.42 to 0.19, p < 0.05). However, aerobic exercise significantly improved the 24-hour mean blood glucose levels in patients with a BMI between 29 and 30 (d = -0.65, 95% CI: -0.94 to -0.36, p < 0.05) and in those with a BMI >30 (d = -0.76, 95% CI: -0.87 to -0.64, p < 0.05).

### 3.6 Test for publication bias

The outcome indicators of the included studies and the symmetrical distribution of the scatter points on both sides of the funnel plot suggest that there is no publication bias (see Figure 10).

### 3.7 Sensitivity analysis

A sensitivity analysis of the included studies, in which each article was excluded one by one until the improvement in the outcome indicators was not obvious, showed that the results of this study meta-analysis were reliable.

### 4 Discussion

# 4.1 Aerobic exercise can improve 24-hour mean blood glucose and HbA1c in patients with T2DM

This study found that aerobic exercise can improve 24-hour mean blood glucose and HbA1c in patients with T2DM, possibly by increasing muscle sensitivity to insulin. This is consistent with Al-Mhanna et al. (2024a), who found that combining aerobic and resistance training may increase muscle glucose uptake and promote favorable changes in body composition, such as reduced adiposity, thereby improving glycemic control and insulin sensitivity. Also,

		erimen			ontrol			Mean Difference	Mean Differen
tudy or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% C
.2.1 0-1 times/week									
Marcotte-Chénard 2024(1)	7.82	1.01	14	8.88	1.5	14	1.1%	-1.06 [-2.01, -0.11]	
Marcotte-Chénard 2024(2)	8.13	1.75	14	8.88	1.5	14	0.6%	-0.75 [-1.96, 0.46]	
). J. Oberlin 2014	5.98	0.49	9	6.62	0.73	9	2.9%	-0.64 [-1.21, -0.07]	
. Myette-Côté 2016	7	1.4	10	7.2	1.3	10	0.7%	-0.20 [-1.38, 0.98]	
. Haxhi 2016(1)	7.21	0.96	9	7.29	1.15	9	1.0%	-0.08 [-1.06, 0.90]	
. Haxhi 2016(2)	7.18	1.58	9	7.29	1.15	9	0.6%	-0.11 [-1.39, 1.17]	
. L. Rees 2019	7.4	1.5	37	7.3	1.4	26	1.8%	0.10 [-0.62, 0.82]	
. W. van Dijk 2012(1)	8.3	0.3	30	9.1	0.4	30	29.5%	-0.80 [-0.98, -0.62]	
R. J. Manders 2010(1)	7.8	0.9	9	9.4	0.8	9		-1.60 [-2.39, -0.81]	
R. J. Manders 2010(2)	8.7	0.7	9	9.4	0.8	9		-0.70 [-1.39, -0.01]	
R. S. Metcalfe 2018(1)	7.74	1.1	11		1.05	11	1.2%	-0.37 [-1.27, 0.53]	
R. S. Metcalfe 2018(2)	7.74		11		1.05	11	1.9%	-0.37 [-1.08, 0.34]	
R. S. Metcalfe 2018(3)		0.87	11		1.05	11	1.5%	-0.58 [-1.39, 0.23]	
Subtotal (95% CI)	7.55	0.07	183	0.11	1.05	172		-0.71 [-0.86, -0.57]	•
leterogeneity: Chi <sup>2</sup> = 15.97, dt	- 12 /D -	- 0.10		:04			1011/0	-011 1 [-0100, -0101 ]	•
est for overall effect: Z = 9.78			,1 - 2.	, ,0					
2.2 2-4 times/week									
. W. van Dijk 2012(2)	8.3	0.3	30	9.1	0.4	30	29.5%	-0.80 [-0.98, -0.62]	
(. M. Winding 2018(1)	7.6	1.3	12	8.8	1.7	7	0.4%	-1.20 [-2.66, 0.26]	
(. M. Winding 2018(2)	7.8	1.6	13	8.8	1.7	7	0.4%	-1.00 [-2.53, 0.53]	
ibtotal (95% CI)			55			44	30.4%	-0.81 [-0.98, -0.63]	◆
leterogeneity: Chi² = 0.35, df = est for overall effect: Z = 8.98			= 0%						
	γ · 0.00	.501)							
.2.3 5-7 times/week	. ·		4.5				1.00		
Karstoft 2013(1)	8.1	0.8	12	8.3	1.1	8	1.2%	-0.20 [-1.09, 0.69]	
(. Karstoft 2013(2)	7.5	0.4	12	8.3	1.1	8		-0.80 [-1.60, -0.00]	
(Karstoft 2017(1)	7.5	0.5	14	8.1	0.6	14		-0.60 [-1.01, -0.19]	
(Karstoft 2017(2)	7.7	0.5	14	8.1	0.6	14	5.6%	-0.40 [-0.81, 0.01]	
1. Munan 2020(1)	7.5	0.7	13	7.5	0.6	12	3.6%	0.00 [-0.51, 0.51]	<u> </u>
1. Munan 2020(2)	7.3	0.9	14	7.5	0.6	12	2.8%	-0.20 [-0.78, 0.38]	
1. Munan 2020(3)	7.6	0.8	13	7.5	0.6	12	3.1%	0.10 [-0.45, 0.65]	
ubtotal (95% CI)			92			80	23.5%	-0.31 [-0.51, -0.11]	•
eterogeneity: Chi² = 7.31, df = est for overall effect: Z = 3.05			= 18%						
otal (95% CI)			330			296	100.0%	-0.65 [-0.75, -0.55]	•
leterogeneity: Chi <sup>2</sup> = 38.45, dt	= 22 (P =	= 0.021	$ ^2 = 43$	3%					<u> </u>
est for overall effect: Z = 13.0	•								-2 -1 0 1
est for subgroup differences:				= 0.000	16) IZ-	96.60			Favours [experimental] Favours
estion subgroup unterences.	010 - 1	4.02, u	- 2 (1	- 0.000	JOJ. I -	00.57			

Al-Mhanna et al. (2023) found that combined aerobic exercise and diet significantly improved HbA1c concentration, fasting blood glucose, fasting plasma insulin, total cholesterol, triglycerides, C-reactive protein and series body composition in obesity and T2DM. Aerobic exercise activates multiple signaling pathways, especially AMP-activated protein kinase (AMPK) and protein kinase B (Akt), which promote the transport of glucose transporter 4 (GLUT4) from the bloodstream to the muscle cell membrane. This enhances muscle sensitivity to insulin, increasing the muscle's ability to absorb and utilize glucose from the bloodstream, and reducing blood glucose levels (Dastbarhagh et al., 2019). Long-term aerobic exercise can sustain this effect, as reflected in a decrease in HbA1c (Qian et al., 2023).

### 4.2 Different periods of aerobic exercise can improve the 24-hour average blood glucose of patients with T2DM

This study concluded that different aerobic exercise periods can improve the 24-hour mean blood glucose in patients with T2DM.

The most significant improvement was observed in the 0–7-day group, followed by the >14-day group, and lastly the 7–14-day group. A prolonged lack of exercise can reduce lipoprotein lipase activity, muscle glucose, and protein transporter activity, impair lipid metabolism, and decrease carbohydrate metabolism (Park et al., 2020). During the initial 0–7 days, participants without a regular exercise habit have not yet adapted to the physiological stimuli induced by exercise, resulting in a rapid increase in insulin sensitivity, with the most pronounced physiological response occurring during this period. As noted by Marcotte-Chénard et al. (2024), a single aerobic exercise session can significantly improve 24-hour mean blood glucose, blood glucose variability, and blood glucose peaks in patients with T2DM.

However, as the duration of exercise is extended to 14 days, the body gradually adapts to the exercise load, meaning it no longer needs to make drastic adjustments to cope with the same intensity of movement. This adaptation slows the improvement in insulin sensitivity, reducing the impact of exercise on the body. Timmons et al. (2005) found that 6 weeks of high-intensity aerobic circuit training significantly increased the mRNA expression levels of platelet reactant protein 4 and  $\alpha 2$ -

$\begin{array}{c c c c c c c c c c c c c c c c c c c $			rimen			ontrol			Mean Difference	Mean Difference
Haxhi 2016(2) 7.18 1.58 9 7.29 1.15 9 0.6% $-0.11[+1.39, 1.17]$ M. Winding 2018(2) 7.8 1.6 13 8.8 1.7 7 0.4% $-1.00[+2.59, 0.53]$ Lis Metafe 2018(3) 7.5 0.87 11 8.11 1.05 11 1.5% $-0.58[+1.39, 0.23]$ Librorgenety. ChP= 0.78, df= 2 (P = 0.67); P = 0% est for overall effect Z = 1.69 (P = 0.09) 4.2 20-40 mins Marcotte-Chénard 2024(1) 7.82 1.01 14 8.88 1.5 14 1.1% $-1.06[+2.01, -0.11]$ Marcotte-Chénard 2024(1) 7.21 0.96 9 7.29 1.15 9 1.0% $-0.08[+1.06, 0.06]$ Haxhi 2016(1) 7.21 0.96 9 7.29 1.15 9 1.0% $-0.08[+1.06, 0.26]$ Haxhi 2016(1) 7.21 0.96 9 7.29 1.15 9 1.0% $-0.08[+1.06, 0.26]$ Haxhi 2016(1) 7.21 0.96 9 7.29 1.15 9 1.0% $-0.08[+1.06, 0.26]$ Haxhi 2016(1) 7.74 1.1 8.11 1.05 11 1.2% $-0.37[+1.27, 0.53]$ E. Metafer 2019(2) 7.74 0.59 11 8.11 1.05 11 1.9% $-0.37[+1.27, 0.53]$ E. Metafer 2019(2) 7.74 0.59 11 8.11 1.05 11 1.9% $-0.37[+1.27, 0.53]$ E. Metafer 2019(2) 7.74 1.5 37 7.3 1.4 26 1.8% $-0.02[+1.38, 0.98]$ J. J. Ghomins Harsott 2016 7 7 1.4 10 7.2 1.3 10 0.7% $-0.20[+1.38, 0.98]$ L. Rees 2019 7.4 1.5 37 7.3 1.4 26 1.8% $-0.00[+1.01, 0.03]$ Karsott 2013(2) 7.5 0.4 12 8.3 1.1 8 1.2% $-0.27[+1.08, 0.82]$ Karsott 2013(2) 7.5 0.4 12 8.3 1.1 8 1.5% $-0.80[+1.60, -0.00]$ Karsott 2013(2) 7.5 0.4 12 8.3 1.1 8 1.5% $-0.60[+1.01, 0.19]$ Karsott 2017(1) 7.5 0.5 14 8.1 0.6 14 5.6% $-0.40[+0.49, 0.00]$ Karsott 2017(1) 7.5 0.5 14 8.1 0.6 14 5.6% $-0.40[+0.40, 0.00]$ Karsott 2017(2) 7.7 0.5 14 8.1 0.6 14 5.6% $-0.40[+0.40, 0.00]$ Karsott 2017(1) 7.5 0.5 14 8.1 0.6 14 5.6% $-0.40[+0.40, 0.00]$ Karsott 2017(2) 7.7 0.5 14 8.1 0.6 12 2.8% $-0.20[+1.08, 0.80]$ Human 2020(2) 7.3 0.9 14 7.5 0.6 12 2.8% $-0.20[+0.74, 0.80]$ Human 2020(3) 7.6 0.8 13 7.5 0.6 12 2.8% $-0.20[+0.74, 0.80]$ Human 2020(3) 7.6 0.8 13 7.5 0.6 12 2.8% $-0.20[+0.74, 0.80]$ Human 2020(3) 7.6 0.8 13 7.5 0.6 12 2.8% $-0.20[+0.74, 0.80]$ Human 2020(3) 7.6 0.8 13 7.5 0.6 12 2.8% $-0.20[+0.74, 0.80]$ Human 2020(3) 7.6 0.8 13 7.5 0.6 12 2.8% $-0.20[+0.74, 0.46]$ Human 2020(3) 7.6 0.8 13 7.5 0.6 12 2.8% $-0.20[+0.74, 0.46]$ Human 20		Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% Cl	IV, Fixed, 95% Cl
M. Winding 2018(2)       7.8       1.6       13       8.8       1.7       7       0.4%       -1.00[ $z$ ,53],0.23]         1: S. Metcalle 2018(3)       7.63       0.87       11       8.11       1.05       11       1.5%       -0.58 [ $z$ ,139,0.23]         1: S. Metcalle 2018(3)       7.63       0.87       11       8.11       1.05       11       1.5%       -0.58 [ $z$ ,139,0.23]         1: Build of the construction of the c										
$\begin{array}{c c c c c c c c c c c c c c c c c c c $										
ubtotal (95% CI) 33 27 2.4% -0.54 [-1.16, 0.08] leterogeneity. ChP = 0.79, df = 2 (P = 0.67); P = 0% estfor overall effect $Z = 1.69$ (P = 0.09) 4.2 20-40 mins .Marcotte-Chénard 2024(2) 8.13 1.75 14 8.88 1.5 14 1.1% -1.06 [-2.01, -0.11] .Marcotte-Chénard 2024(2) 8.13 1.75 14 8.88 1.5 14 0.6% -0.75 [-1.96, 0.46] .Marcotte-Chénard 2024(2) 8.13 1.75 14 8.88 1.7 1 0.4% -0.075 [-1.96, 0.46] .Marcotte-Chénard 2024(2) 8.13 0.7 9 9.4 0.8 9 2.0% -0.70 [-1.39, -0.62] .M. Winding 2018(1) 7.6 1.3 12 8.8 1.7 7 0.4% -1.20 [-2.66, 0.26] .M. Winding 2018(1) 7.74 1.1 11 8.11 1.05 11 1.2% -0.37 [-1.27, 0.53] .S. Metcaife 2018(2) 7.74 0.59 11 8.11 1.05 11 1.2% -0.37 [-1.08, 0.34] ubtotal (95% CI) 10 105 37.6% -0.75 [-0.91, -0.59] .Karstot 2013(2) 7.5 0.4 12 8.3 1.1 8 1.2% -0.20 [-1.38, 0.88] L. Rees 2019 7 1.4 10 7.2 1.3 10 0.7% -0.20 [-1.38, 0.88] L. Rees 2019 7 1.4 10 7.2 1.3 10 0.7% -0.20 [-1.38, 0.88] .Karstot 2013(1) 8.1 0.8 12 8.3 1.1 8 1.2% -0.20 [-1.09, 0.68] .Karstot 2013(2) 7.5 0.4 12 8.3 1.1 8 1.2% -0.20 [-1.09, 0.68] .Karstot 2017(1) 7.5 0.5 14 8.1 0.6 14 5.6% -0.04 [0.81, 0.01] .Karstot 2017(2) 7.7 0.5 14 8.1 0.6 14 5.6% -0.04 [0.81, 0.01] .Karstot 2017(2) 7.7 0.5 14 8.1 0.6 14 5.6% -0.04 [0.81, 0.01] .Munan 2020(3) 7.6 0.8 13 7.5 0.6 12 2.8% -0.05 [-0.71, -0.46] .Munan 2020(3) 7.6 0.8 13 7.5 0.6 12 3.1% 0.10 [-0.45, 0.68] .J. Manders 2010(1) 7.8 0.9 9 9.4 0.8 9 1.5% -1.60 [-2.39, 0.81] .J. Manders 2010(1) 7.8 0.9 9 9.4 0.8 9 1.5% -1.60 [-2.39, 0.81] .J. Manders 2010(1) 7.8 0.9 9 9.4 0.8 9 1.5% -1.60 [-2.39, 0.81] .J. Manders 2010(1) 7.8 0.9 9 9.4 0.8 9 1.5% -1.60 [-2.39, 0.81] .J. Manders 2010(1) 7.8 0.9 9 9.4 0.8 9 1.5% -1.60 [-2.39, 0.81] .J. Manders 2010(1) 7.8 0.9 9 9.4 0.8 9 1.5% -1.60 [-2.39, 0.81] .J. Manders 2010(1) 7.8 0.9 9 9.4 0.8 9 1.5% -1.60 [-2.39, 0.81] .J. Manders 2010(1) 7.8 0.9 9 9.4 0.8 9 1.5% -1.60 [-2.39, 0.81] .J. Manders 2010(1) 7.8 0.9 9 9.4 0.8 9 1.5% -1.60 [-2.39, 0.81] .J. Manders 2010(1) 7.8 0.9 9 9.4 0.8 9 1.5% -1.60 [-2.39, 0.81] .J. Manders 2010(1) 7.8										
leterogeneily: $Ch^{\mu} = 0.79$ , $df = 2$ ( $P = 0.67$ ); $P = 0\%$ est for overall effect $Z = 1.69$ ( $P = 0.09$ ) <b>4.2 20.40 mins</b> . Marcotte-Chénard 2024(1) 7.82 1.01 14 8.88 1.5 14 1.1% -1.06 [-2.01, -0.11] . Marcotte-Chénard 2024(2) 8.13 1.75 14 8.88 1.5 14 0.6% -0.75 [-1.96, 0.46] . Haxhi 2016(1) 7.21 0.96 9 7.29 1.15 9 1.0% -0.08 [-1.06, 0.90] . W. van Dijk 2012(2) 8.3 0.3 30 8.1 0.4 30 29.5% -0.80 [-0.98, 0.62] . M. Winding 2018(1) 7.6 1.3 12 8.8 1.7 7 0.4% -1.20 [-2.66, 0.26] . J. Manders 2010(2) 8.7 0.7 9 9.4 0.8 9 2.0% -0.70 [-1.39, 0.01] . S. Metcaffe 2018(1) 7.74 1.1 11 8.11 1.05 11 1.9% -0.37 [-1.08, 0.34] <b>ubtotal</b> (95% CI) 110 105 37.6% -0.75 [-0.91, -0.59] eterogeneity: $Ch^{\mu} = 4.88$ , $df = 7$ ( $P = 0.70$ ); $P = 0\%$ est for overall effect $Z = 9.31$ ( $P < 0.00001$ ) <b>4.3 40-60 mins</b> . J. Oberlin 2014 5.98 0.49 9 6.62 0.73 9 2.9% -0.64 [-1.21, -0.07] . Myethe-Côté 2016 7 1.4 10 7.2 1.3 10 0.7% -0.20 [-1.38, 0.89] . L. Rees 2019 7.4 1.5 37 7.3 1.4 26 1.8% 0.10 [-0.62, 0.62] . Karstoft 2013(2) 7.5 0.4 12 8.3 1.1 8 1.5% -0.80 [-1.60, -0.00] . Karstoft 2013(2) 7.5 0.4 12 8.3 1.1 8 1.5% -0.80 [-1.60, -0.01] . Karstoft 2013(2) 7.5 0.4 12 8.3 1.1 8 1.5% -0.80 [-1.61, -0.01] . Karstoft 2013(2) 7.5 0.7 13 7.5 0.6 12 3.6% 0.00 [-0.81, 0.01] . Karstoft 2013(2) 7.5 0.7 13 7.5 0.6 12 3.6% 0.00 [-0.74, 0.46] . J. Manders 2010(1) 7.8 0.9 9 9.4 0.8 9 1.5% -1.60 [-2.39, -0.81] . Munan 2020(2) 7.3 0.9 14 7.5 0.6 12 3.1% 0.00 [-0.45, 0.65] . J. Manders 2010(1) 7.8 0.9 9 9.4 0.8 9 1.5% -1.60 [-2.39, -0.81] . Munan 2020(3) 7.6 0.8 13 7.5 0.6 12 3.1% 0.00 [-0.74, 0.46] eterogeneity: $Ch^{\mu} = 30.29$ , $df = 11$ ( $P = 0.001$ ); $P = 64\%$ est for overall effect $Z = 13.07$ ( $P < 0.00001$ ) <b>40 (95% CI) 330 296 100.0% -0.65 [-0.75, -0.55]</b> <b>40 (browerall effect</b> $Z = 2.07 (P = 0.002)$ ; $P = 43\%$ est for overall effect $Z = 2.07 (P < 0.00001)$		7.53	0.87		8.11	1.05				
est for overall effect Z = 1.69 (P = 0.09)         4.2 20-40 mins         Marcotte-Chénard 2024(1)       7.82       1.01       14       8.88       1.5       14       1.1%       -1.06 [-2.01, -0.11]         Marcotte-Chénard 2024(2)       8.13       1.75       14       8.88       1.5       14       0.6%       -0.06 [-1.06, 0.90]         W. Winding 2018(1)       7.24       1.3       12       8.8       1.7       0.4%       -1.20 [-2.66, 0.26]         J. Manders 2010(2)       8.7       0.7       9       9.4       0.8       9       2.0%       -0.70 [-1.39, -0.01]         S. Metcale 2018(1)       7.74       1.1       11       1.1       1.1       1.2%       -0.37 [-1.08, 0.34]         Ubtotal (95% CI)       110       105       37.6%       -0.75 [-0.91, -0.59]       •         I eterogeneity: Chi² 4 68, df = 7 (P = 0.70); P = 0%       est for overall effect Z = 9.31 (P < 0.00001)							27	2.4%	-0.54 [-1.16, 0.08]	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	-			= 0%						
Marcotte-Chénard 2024(2)       8.13       1.75       14       8.88       1.5       14       0.6%       -0.75 [-1.96, 0.46]         Haxhi 2016(1)       7.21       0.96       9       7.29       1.15       9       1.0%       -0.08 [-0.98, 0.62]         M. Winding 2018(1)       7.6       1.3       12       8.8       1.7       7       0.4%       -1.20 [-2.66, 0.26]         M. Winding 2018(1)       7.6       1.3       12       8.8       1.7       7       0.4%       -1.20 [-2.66, 0.26]         S. Metadife 2018(2)       7.74       0.59       11       8.11       1.05       11       1.9%       -0.37 [-1.27, 0.53]         S. Metadife 2018(2)       7.74       0.59       11       8.11       1.05       11       1.9%       -0.37 [-1.08, 0.34]         ubtotal (95% Ch)       10       105       37.6%       -0.75 [-0.91, -0.59]	.4.2 20-40 mins									
Marcotte-Chénard 2024(2)       8.13       1.75       14       8.88       1.5       14       0.6%       -0.75 [-1.96, 0.46]         Haxhi 2016(1)       7.21       0.96       9       7.29       1.15       9       1.0%       -0.08 [-0.98, 0.62]         M. Winding 2018(1)       7.6       1.3       12       8.8       1.7       7       0.4%       -1.20 [-2.66, 0.26]         M. Winding 2018(1)       7.6       1.3       12       8.8       1.7       7       0.4%       -1.20 [-2.66, 0.26]         S. Metadife 2018(2)       7.74       0.59       11       8.11       1.05       11       1.9%       -0.37 [-1.27, 0.53]         S. Metadife 2018(2)       7.74       0.59       11       8.11       1.05       11       1.9%       -0.37 [-1.08, 0.34]         ubtotal (95% Ch)       10       105       37.6%       -0.75 [-0.91, -0.59]	Marcotte-Chénard 2024(1)	7.82	1.01	14	8.88	1.5	14	1.1%	-1.06 [-2.01, -0.11]	
Haxhi 2016(1) 7.21 0.96 9 7.29 1.15 9 1.0% $-0.08[-1.06, 0.90]$ W. van Dijk 2012(2) 8.3 0.3 30 9.1 0.4 30 29.5% $-0.80[-1.08, 0.40]$ W. van Dijk 2012(2) 8.7 0.7 9 9.4 0.8 9 2.0% $-0.70[-1.39, -0.01]$ S. Metcalfe 2018(1) 7.74 1.1 11 8.11 1.05 11 1.2% $-0.37[-1.27, 0.53]$ S. Metcalfe 2018(2) 7.74 0.59 11 8.11 1.05 11 1.9% $-0.37[-1.08, 0.34]$ ubtotal (95% C) 10 10 105 37.6% $-0.75[-0.94]$ , 0.59] Leterogeneity. Ch <sup>2</sup> = 4.68, df = 7 ( $P = 0.70$ ); $P = 0$ % est for overall effect Z = 9.31 ( $P < 0.00001$ ) Karstoft 2013(1) 8.1 0.8 12 8.3 1.1 8 1.5% $-0.20[-1.38, 0.89]$ L. Rees 2019 7.4 1.5 37 7.3 1.4 26 1.8% 0.10[-0.62, 0.82] W. van Dijk 2012(1) 8.3 0.3 30 9.1 0.4 30 29.5% $-0.80[-1.09, -0.68]$ L. Rees 2019 7.4 1.5 37 7.3 1.4 26 1.8% 0.10[-0.62, 0.82] W. van Dijk 2012(1) 8.3 0.3 30 9.1 0.4 30 29.5% $-0.80[-1.09, -0.68]$ L. Rees 2019 7.4 1.5 37 7.3 1.4 26 1.8% 0.10[-0.62, 0.82] W. van Dijk 2012(1) 8.1 0.8 12 8.3 1.1 8 1.5% $-0.20[-1.09, -0.68]$ L. Karstoft 2013(2) 7.5 0.4 12 8.3 1.1 8 1.5% $-0.80[-1.00, -0.00]$ Karstoft 2017(1) 7.5 0.5 14 8.1 0.6 14 5.6% $-0.40[-0.81, 0.01]$ Munan 2020(2) 7.3 0.9 14 7.5 0.6 12 3.1% $0.10[-0.45, 0.65]$ L. Munan 2020(2) 7.3 0.9 14 7.5 0.6 12 3.1% $0.10[-0.45, 0.65]$ L. Munan 2020(2) 7.3 0.9 14 7.5 0.6 12 3.1% $0.10[-0.45, 0.65]$ L. Munan 2020(2) 7.3 0.9 14 7.5 0.6 12 3.1% $0.10[-0.45, 0.65]$ L. Munan 2020(2) 7.3 0.9 14 7.5 0.6 12 3.1% $0.10[-0.45, 0.65]$ L. Munan 2020(3) 7.6 0.8 13 7.5 0.6 12 3.1% $0.10[-0.45, 0.65]$ L. Munan 2020(3) 7.6 0.8 13 7.5 0.6 12 3.1% $0.10[-0.45, 0.65]$ L. Munan 2020(3) 7.6 0.8 13 7.5 0.6 12 3.1% $0.10[-0.45, 0.65]$ L. Munan 2020(3) 7.6 0.8 13 7.5 0.6 12 3.1% $0.10[-0.45, 0.65]$ L. Munan 2020(3) 7.6 0.8 13 7.5 0.6 12 3.1% $0.10[-0.45, 0.65]$ L. Munan 2020(4) 7.8 0.9 9 4.4 0.8 9 1.5% $-1.60[-2.39, -0.81]$ Hutotal (95% C) 187 780.4 10.8 79.4 10.8 70 780.4 10.8 10.4 10.8 10.8 10.8 10.8 10.8 10.8 10.8 10.8	. Marcotte-Chénard 2024(2)			14						
W. van Dijk $2012(2)$ 8.3 0.3 30 9.1 0.4 30 29.5% -0.80 [0.98, -0.62] M. Winding 2018(1) 7.6 1.3 12 8.8 1.7 7 0.4% -1.20 [2.66, 0.26] J. J. Manders 2010(2) 8.7 0.7 9 9.4 0.8 9 2.0% -0.70 [-1.39, -0.01] S. Metcaife 2018(1) 7.74 1.1 11 8.11 1.05 11 1.2% -0.37 [-1.27, 0.53] S. Metcaife 2018(2) 7.74 0.59 11 8.11 1.05 11 1.9% -0.37 [-1.08, 0.34] ubtotal (95% CI) 110 105 37.6% -0.75 [-0.91, -0.59] Karstoft 2017(2) 7.5 0.4 12 8.3 1.1 8 1.2% -0.20 [-1.38, 0.98] L. Rees 2019 7.4 1.5 37 7.3 1.4 26 1.8% 0.10 [-0.62, 0.82] W. van Dijk 2012(1) 8.3 0.3 30 9.1 0.4 30 29.5% -0.80 [-1.09, 0.69] Karstoft 2013(2) 7.5 0.4 12 8.3 1.1 8 1.2% -0.20 [-1.38, 0.98] L. Rees 2019 7.4 1.5 37 7.3 1.4 26 1.8% 0.00 [-0.61, 0.01] Karstoft 2013(2) 7.5 0.4 12 8.3 1.1 8 1.2% -0.20 [-1.09, 0.69] Karstoft 2017(2) 7.5 0.4 12 8.3 1.1 8 1.2% -0.20 [-1.09, 0.69] Karstoft 2017(2) 7.5 0.4 12 8.3 1.1 8 1.2% -0.20 [-1.09, 0.69] Karstoft 2017(2) 7.7 0.5 14 8.1 0.6 14 5.6% -0.40 [-0.81, 0.01] Munan 2020(1) 7.5 0.7 13 7.5 0.6 12 3.6% 0.00 [-0.51, 0.51] U. Munan 2020(2) 7.3 0.9 14 7.5 0.6 12 3.6% 0.00 [-0.51, 0.51] Munan 2020(2) 7.3 0.9 14 7.5 0.6 12 3.6% 0.00 [-0.51, 0.51] U. Munan 2020(2) 7.3 0.9 14 7.5 0.6 12 3.6% 0.00 [-0.51, 0.51] U. Munan 2020(2) 7.3 0.9 14 7.5 0.6 12 3.6% 0.00 [-0.51, 0.51] U. Munan 2020(2) 7.3 0.9 14 7.5 0.6 12 3.6% 0.00 [-0.51, 0.51] U. Munan 2020(2) 7.3 0.9 14 7.5 0.6 12 3.6% 0.00 [-0.51, 0.51] U. Munan 2020(3) 7.6 0.8 13 7.5 0.6 12 3.6% 0.00 [-0.51, 0.51] U. Munan 2020(3) 7.6 0.8 13 7.5 0.6 12 3.6% 0.00 [-0.71, -0.46] Heterogeneity: Chi <sup>2</sup> = 30.6 (P < 0.0001); P = 64% est for overall effect Z = 91.6 (P < 0.0001); P = 64% est for overall effect Z = 13.07 (P < 0.00001)	. Haxhi 2016(1)			9						
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	. W. van Dijk 2012(2)	8.3	0.3	30		0.4	30	29.5%		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	. M. Winding 2018(1)	7.6	1.3	12	8.8	1.7	7			
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	2. J. Manders 2010(2)									
$\begin{array}{c c c c c c c c c c c c c c c c c c c $										
ubtotal (95% Cl)       110       105       37.6%       -0.75 [-0.91, -0.59]         leterogeneity: Chi <sup>P</sup> = 4.68, df = 7 (P = 0.70); P = 0%       est for overall effect: Z = 9.31 (P < 0.00001)	2. S. Metcalfe 2018(2)									
leterogeneity: $Chi^{P} = 4.68, df = 7 (P = 0.70); P = 0\%$ est for overall effect: $Z = 9.31 (P < 0.00001)$ <b>4.3 40-60 mins</b> . J. Oberlin 2014 5.98 0.49 9 6.62 0.73 9 2.9% -0.64 [-1.21, -0.07] . Myette-Côté 2016 7 1.4 10 7.2 1.3 10 0.7% -0.20 [-1.38, 0.98] . L. Rees 2019 7.4 1.5 37 7.3 1.4 26 1.8% 0.10 [-0.62, 0.82] . W. van Dijk 2012(1) 8.3 0.3 30 9.1 0.4 30 29.5% -0.80 [-0.98, -0.62] . Karstoft 2013(2) 7.5 0.4 12 8.3 1.1 8 1.2% -0.20 [-1.09, 0.68] . Karstoft 2013(2) 7.5 0.4 12 8.3 1.1 8 1.5% -0.80 [-1.60, -0.00] . Karstoft 2017(1) 7.5 0.5 14 8.1 0.6 14 5.6% -0.40 [-0.61, 0.51] . Munan 2020(2) 7.7 0.5 14 8.1 0.6 12 3.6% -0.00 [-0.61, 0.51] . Munan 2020(2) 7.3 0.9 14 7.5 0.6 12 3.8% -0.20 [-0.78, 0.38] . Munan 2020(2) 7.3 0.9 14 7.5 0.6 12 3.1% 0.10 [-0.45, 0.65] . J. Manders 2010(1) 7.8 0.9 9 9.4 0.8 9 1.5% -1.60 [-2.39, -0.81] ubtotal (95% CI) 187 164 59.9% -0.59 [-0.71, -0.46] leterogeneity: $Chi^{P} = 38.45, df = 22 (P = 0.02); I^{P} = 43\%$ est for overall effect: $Z = 9.16 (P < 0.00001)$				110			105			•
est for overall effect: Z = 9.31 (P < 0.00001)		7 (P = 0	.70): 12	= 0%						
4.3 40-60 mins        J. Oberlin 2014       5.98       0.49       9       6.62       0.73       9       2.9%       -0.64 [-1.21, -0.07]        Myette-Côté 2016       7       1.4       10       7.2       1.3       10       0.7%       -0.20 [-1.38, 0.98]        L. Rees 2019       7.4       1.5       37       7.3       1.4       26       1.8%       0.10 [-0.62, 0.82]        Karstoft 2013(1)       8.1       0.8       1.2       8.3       1.1       8       1.2%       -0.20 [-1.09, 0.69]        Karstoft 2013(2)       7.5       0.4       12       8.3       1.1       8       1.5%       -0.80 [-1.60, -0.00]        Karstoft 2017(1)       7.5       0.5       14       8.1       0.6       14       5.6%       -0.40 [-0.81, 0.01]        Karstoft 2017(2)       7.7       0.5       14       8.1       0.6       12       3.6%       0.00 [-0.51, 0.51]        Munan 2020(2)       7.3       0.9       14       7.5       0.6       12       3.1%       0.10 [-0.45, 0.65]        J. Manders 2010(1)       7.8       0.9       9       9.4       0.8       9       1.5%       -1.60 [-2.39, -0.81]										
J. Oberlin 2014       5.98 $0.49$ 9 $6.62$ $0.73$ 9 $2.9\%$ $-0.64$ [-1.21, $-0.07$ ]         Myette-Côté 2016       7 $1.4$ $10$ $7.2$ $1.3$ $10$ $0.7\%$ $-0.20$ [-1.38, 0.98]         L. Rees 2019 $7.4$ $1.5$ $37$ $7.3$ $1.4$ $26$ $1.8\%$ $0.10$ [ $-0.62$ , 0.82]         W. van Dijk 2012(1) $8.3$ $0.3$ $30$ $9.1$ $0.4$ $30$ $29.5\%$ $-0.80$ [ $-1.09$ , 0.62]         Karstoft 2013(2) $7.5$ $0.4$ $12$ $8.3$ $1.1$ $8$ $1.2\%$ $-0.20$ [ $-1.09$ , 0.69]         Karstoft 2017(2) $7.5$ $0.4$ $12$ $8.3$ $1.1$ $8$ $1.5\%$ $-0.60$ [ $-1.01, -0.19$ ]         Karstoft 2017(2) $7.7$ $0.5$ $14$ $8.1$ $0.6$ $12$ $3.6\%$ $0.00$ [ $-0.51, 0.51$ ]         Munan 2020(2) $7.3$ $0.9$ $14$ $7.5$ $0.6$ $12$ $3.6\%$ $0.00$ [ $-0.45, 0.65$ ] $0.00$ [ $-0.45, 0.65$ ]          Munan 2020(3) $7.6$ $0.8$ $13$		,								
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	.4.3 40-60 mins									
L. Rees 2019 7.4 1.5 37 7.3 1.4 26 1.8% $0.10[-0.62, 0.82]$ W. van Dijk 2012(1) 8.3 0.3 30 9.1 0.4 30 29.5% $-0.80[-0.98, -0.62]$ Karstoft 2013(2) 7.5 0.4 12 8.3 1.1 8 1.2% $-0.20[-1.09, 0.69]$ Karstoft 2017(1) 7.5 0.5 14 8.1 0.6 14 5.6% $-0.40[-0.81, 0.01]$ Karstoft 2017(2) 7.7 0.5 14 8.1 0.6 14 5.6% $-0.40[-0.81, 0.01]$ Karstoft 2017(2) 7.7 0.5 14 8.1 0.6 14 5.6% $-0.40[-0.81, 0.01]$ Karstoft 2017(2) 7.7 0.5 14 8.1 0.6 12 3.6% $0.00[-0.51, 0.51]$ Munan 2020(2) 7.3 0.9 14 7.5 0.6 12 3.6% $0.00[-0.51, 0.51]$ Munan 2020(3) 7.6 0.8 13 7.5 0.6 12 3.1% $0.10[-0.45, 0.65]$ . Munan 2020(3) 7.6 0.8 13 7.5 0.6 12 3.1% $0.10[-0.45, 0.65]$ . Munan 2020(3) 7.6 0.8 13 7.5 0.6 12 3.1% $0.10[-0.45, 0.65]$ . Munan 2020(3) 7.6 0.8 13 7.5 0.6 12 0.3% $-0.59[-0.71, -0.46]$ ubtotal (95% CI) 187 164 59.9% $-0.59[-0.71, -0.46]$ leterogeneity: Chi <sup>2</sup> = 30.29, df = 11 (P = 0.001); I <sup>2</sup> = 64% est for overall effect: Z = 9.16 (P < 0.00001) total (95% CI) 330 296 100.0% $-0.65[-0.75, -0.55]$ -2 -1 0 + 15 Eavours [experimental] Eavours [experimenta	). J. Oberlin 2014	5.98	0.49	9		0.73	9	2.9%	-0.64 [-1.21, -0.07]	
W. van Dijk 2012(1)       8.3       0.3       30       9.1       0.4       30       29.5%       -0.80 [-0.99, -0.62]         Karstoft 2013(1)       8.1       0.8       12       8.3       1.1       8       1.2%       -0.20 [-1.09, 0.69]         Karstoft 2013(2)       7.5       0.4       12       8.3       1.1       8       1.2%       -0.20 [-1.09, 0.69]         Karstoft 2017(2)       7.5       0.4       12       8.3       1.1       8       1.5%       -0.60 [-1.01, -0.19]         Karstoft 2017(2)       7.7       0.5       14       8.1       0.6       14       5.6%       -0.40 [-0.81, 0.01]         Munan 2020(1)       7.5       0.7       13       7.5       0.6       12       3.6%       -0.20 [-0.78, 0.38]         Munan 2020(2)       7.3       0.9       14       7.5       0.6       12       3.1%       0.10 [-0.45, 0.65]         Munan 2020(3)       7.6       0.8       13       7.5       0.6       12       3.1%       0.10 [-0.45, 0.65]         Munders 2010(1)       7.8       0.9       9       9.4       0.8       9       1.5%       -1.60 [-2.39, -0.81]         Ieterogeneity: Chi <sup>P</sup> = 30.29, df = 11 (P = 0.001); I <sup>P</sup> = 64%	. Myette-Côté 2016	7	1.4	10	7.2	1.3	10	0.7%	-0.20 [-1.38, 0.98]	
. Karstoft 2013(1)       8.1       0.8       12       8.3       1.1       8       1.2% $-0.20[+1.09, 0.69]$ . Karstoft 2013(2)       7.5       0.4       12       8.3       1.1       8       1.5% $-0.80[-1.60, -0.00]$ . Karstoft 2017(1)       7.5       0.5       1.4       8.1       0.6       1.4       5.6% $-0.40[-0.81, 0.01]$ . Karstoft 2017(2)       7.7       0.5       1.4       8.1       0.6       1.4       5.6% $-0.40[-0.81, 0.01]$ . Munan 2020(1)       7.5       0.7       1.3       7.5       0.6       1.2       3.6% $0.00[-0.51, 0.51]$ . Munan 2020(2)       7.3       0.9       1.4       7.5       0.6       1.2       3.1% $0.10[-0.45, 0.65]$ . J. Manders 2010(1)       7.8       0.9       9       9.4       0.8       9       1.5% $-1.60[-2.39, -0.81]$ . ubtotal (95% Cl)       187       164       59.9% $-0.59[-0.71, -0.46]$ $-2$ $-1$ $-2$ $-1$ $-2$ $-1$ $-2$ $-1$ $-2$ $-1$ $-2$ $-1$ $-2$ $-1$ $-2$ $-1$ $-2$ <	. L. Rees 2019	7.4	1.5	37	7.3	1.4	26	1.8%	0.10 [-0.62, 0.82]	
: Karstoft 2013(2)       7.5       0.4       12       8.3       1.1       8       1.5% $-0.80$ [ $-1.60$ , $-0.00$ ]         :Karstoft 2017(1)       7.5       0.5       14       8.1       0.6       14       5.6% $-0.40$ [ $-0.81$ , $0.01$ ]         :Karstoft 2017(2)       7.7       0.5       14       8.1       0.6       14       5.6% $-0.40$ [ $-0.81$ , $0.01$ ]         :Munan 2020(1)       7.5       0.7       13       7.5       0.6       12       3.6% $0.00$ [ $-0.78$ , $0.03$ ]         :Munan 2020(2)       7.3       0.9       14       7.5       0.6       12       3.1% $0.10$ [ $-0.45$ , $0.65$ ]         :.Manders 2010(1)       7.8       0.9       9       9.4       0.8       9       1.5% $-1.60$ [ $-2.39$ , $-0.81$ ]         ubtotal (95% CI)       187       164       59.9% $-0.59$ [ $-0.71$ , $-0.46$ ] $-2$ $-1$ $-2$ $-1$ $-2$ $-1$ $0$ tetrogeneity: Chi <sup>P</sup> = 30.29, df = 11 (P = 0.001); P = 64%       296       100.0% $-0.65$ [ $-0.75$ , $-0.55$ ] $-2$ $-1$ $0$ $-2$ $-1$ $0$ $-2$ $-1$ $0$ $-2$ $-1$ $0$ <td>. W. van Dijk 2012(1)</td> <td>8.3</td> <td>0.3</td> <td>30</td> <td>9.1</td> <td>0.4</td> <td>30</td> <td>29.5%</td> <td>-0.80 [-0.98, -0.62]</td> <td></td>	. W. van Dijk 2012(1)	8.3	0.3	30	9.1	0.4	30	29.5%	-0.80 [-0.98, -0.62]	
LKarstoft 2017(1)       7.5       0.5       14       8.1       0.6       14       5.6% $-0.60[-1.01, -0.19]$ LKarstoft 2017(2)       7.7       0.5       14       8.1       0.6       14       5.6% $-0.40[-0.81, 0.01]$ L Munan 2020(1)       7.5       0.7       13       7.5       0.6       12       3.6% $0.00[-0.51, 0.51]$ L Munan 2020(2)       7.3       0.9       14       7.5       0.6       12       2.8% $-0.20[-0.78, 0.38]$ L Munan 2020(3)       7.6       0.8       13       7.5       0.6       12       3.1% $0.10[-0.45, 0.65]$ .J Manders 2010(1)       7.8       0.9       9       9.4       0.8       9 $1.5\%$ $-1.60[-2.39, -0.81]$ ubtotal (95% CI)       187       164       59.9% $-0.59[-0.71, -0.46]$ $-2$ $-2$ $-1$ $-2$ $-1$ $-2$ $-1$ $-2$ $-1$ $-2$ $-1$ $-2$ $-1$ $-2$ $-1$ $-2$ $-2$ $-1$ $-2$ $-1$ $-2$ $-1$ $-2$ $-1$ $-2$ $-1$ $-2$ $-1$ $-2$	(. Karstoft 2013(1)	8.1	0.8	12	8.3	1.1	8	1.2%	-0.20 [-1.09, 0.69]	
LKarstoft 2017(2)       7.7       0.5       14       8.1       0.6       14       5.6% $-0.40$ [-0.81, 0.01]         L Munan 2020(1)       7.5       0.7       13       7.5       0.6       12       3.6%       0.00 [-0.51, 0.51]         L Munan 2020(2)       7.3       0.9       14       7.5       0.6       12       2.8% $-0.20$ [-0.78, 0.38]         L Munan 2020(3)       7.6       0.8       13       7.5       0.6       12       2.8% $-0.20$ [-0.78, 0.38]         J. Manders 2010(1)       7.8       0.9       9       9.4       0.8       9       1.5% $-1.60$ [-2.39, -0.81]         ubtotal (95% CI)       187       164       59.9% $-0.59$ [-0.71, -0.46]         leterogeneity: Chi <sup>2</sup> = 30.29, df = 11 (P = 0.001); I <sup>2</sup> = 64%       296       100.0% $-0.65$ [-0.75, -0.55]         otal (95% CI)       330       296       100.0% $-0.65$ [-0.75, -0.55] $-2$ ieterogeneity: Chi <sup>2</sup> = 38.45, df = 22 (P = 0.02); I <sup>2</sup> = 43% $-2$ $-1$ $0$ $-2$ $-1$ $0$ $-2$ $-1$ $0$ $-2$ $-1$ $0$ $-2$ $-1$ $0$ $-2$ $-1$ $0$ <	. Karstoft 2013(2)	7.5	0.4	12	8.3	1.1	8	1.5%	-0.80 [-1.60, -0.00]	
I. Munan 2020(1)       7.5       0.7       13       7.5       0.6       12       3.6%       0.00 [-0.51, 0.51]         I. Munan 2020(2)       7.3       0.9       14       7.5       0.6       12       2.8%       -0.20 [-0.78, 0.38]         I. Munan 2020(3)       7.6       0.8       13       7.5       0.6       12       3.1%       0.10 [-0.45, 0.65]         J. Manders 2010(1)       7.8       0.9       9       9.4       0.8       9       1.5%       -1.60 [-2.39, -0.81]         ubtotal (95% CI)       187       164       59.9%       -0.59 [-0.71, -0.46]	.Karstoft 2017(1)	7.5	0.5	14	8.1	0.6	14	5.6%	-0.60 [-1.01, -0.19]	_ <u>.</u>
I. Munan 2020(2)       7.3       0.9       14       7.5       0.6       12       2.8% $-0.20$ [-0.78, 0.38]         I. Munan 2020(3)       7.6       0.8       13       7.5       0.6       12       3.1%       0.10 [-0.45, 0.65]         J. Manders 2010(1)       7.8       0.9       9       9.4       0.8       9       1.5% $-1.60$ [-2.39, -0.81]         ubtotal (95% CI)       187       164       59.9% $-0.59$ [-0.71, -0.46] $-0.59$ [-0.71, -0.46]         leterogeneity: Chi <sup>2</sup> = 30.29, df = 11 (P = 0.001); I <sup>2</sup> = 64%       296       100.0% $-0.65$ [-0.75, -0.55] $-2$ $-1$ $-1$ otal (95% CI)       330       296       100.0% $-0.65$ [-0.75, -0.55] $-2$ $-1$ $-1$ $-2$ $-1$ $0$ $-2$ $-1$ $0$ $1$ tetrogeneity: Chi <sup>2</sup> = 38.45, df = 22 (P = 0.02); I <sup>2</sup> = 43%       est for overall effect: Z = 13.07 (P < 0.00001)	.Karstoft 2017(2)	7.7	0.5	14	8.1	0.6	14	5.6%	-0.40 [-0.81, 0.01]	
L Munan 2020(3) 7.6 0.8 13 7.5 0.6 12 3.1% 0.10 [-0.45, 0.65] .J. Manders 2010(1) 7.8 0.9 9 9.4 0.8 9 1.5% -1.60 [-2.39, -0.81] ubtotal (95% CI) 187 164 59.9% -0.59 [-0.71, -0.46] leterogeneity: Chi <sup>™</sup> = 30.29, df = 11 (P = 0.001); I <sup>™</sup> = 64% est for overall effect: Z = 9.16 (P < 0.00001) otal (95% CI) 330 296 100.0% -0.65 [-0.75, -0.55] leterogeneity: Chi <sup>™</sup> = 38.45, df = 22 (P = 0.02); I <sup>™</sup> = 43% est for overall effect: Z = 13.07 (P < 0.00001) Favours [experimental] Favours [experimental]	1. Munan 2020(1)	7.5	0.7	13	7.5	0.6	12	3.6%	0.00 [-0.51, 0.51]	
L. J. Manders 2010(1)       7.8       0.9       9       9.4       0.8       9       1.5%       -1.60 [-2.39, -0.81]         ubtotal (95% CI)       187       164       59.9%       -0.59 [-0.71, -0.46]         leterogeneity:       Chi <sup>2</sup> = 30.29, df = 11 (P = 0.001); I <sup>2</sup> = 64%         est for overall effect: Z = 9.16 (P < 0.00001)	1. Munan 2020(2)	7.3	0.9	14	7.5	0.6	12	2.8%	-0.20 [-0.78, 0.38]	
ubtotal (95% CI)       187       164       59.9%       -0.59 [-0.71, -0.46]         leterogeneity: Chi <sup>2</sup> = 30.29, df = 11 (P = 0.001); I <sup>2</sup> = 64%       est for overall effect: Z = 9.16 (P < 0.00001)	1. Munan 2020(3)	7.6	0.8	13	7.5	0.6	12	3.1%	0.10 [-0.45, 0.65]	
leterogeneity: Chi <sup>2</sup> = 30.29, df = 11 (P = 0.001); l <sup>2</sup> = 64% est for overall effect: Z = 9.16 (P < 0.00001) otal (95% Cl) 330 296 100.0% -0.65 [-0.75, -0.55] leterogeneity: Chi <sup>2</sup> = 38.45, df = 22 (P = 0.02); l <sup>2</sup> = 43% est for overall effect: Z = 13.07 (P < 0.00001) Eavours (experimental) Eavours (control or control or contro	2. J. Manders 2010(1)	7.8	0.9		9.4	0.8	9	1.5%	-1.60 [-2.39, -0.81]	
est for overall effect: Z = 9.16 (P < 0.00001) otal (95% CI) 330 296 100.0% -0.65 [-0.75, -0.55] leterogeneity: Chi <sup>2</sup> = 38.45, df = 22 (P = 0.02); i <sup>2</sup> = 43% est for overall effect: Z = 13.07 (P < 0.00001) Favours (experimental) Favours (control of the second sec	ubtotal (95% CI)			187			164	<b>59.9</b> %	-0.59 [-0.71, -0.46]	◆
otal (95% Cl)         330         296         100.0%         -0.65         -0.055         -0.055           leterogeneity: Chi <sup>a</sup> = 38.45, df = 22 (P = 0.02); I <sup>a</sup> = 43%         -2         -1         0         1           est for overall effect: Z = 13.07 (P < 0.00001)	leterogeneity: Chi² = 30.29, df	= 11 (P =	= 0.001	);	64%					
leterogeneity: Chi <sup>#</sup> = 38.45, df = 22 (P = 0.02); i <sup>#</sup> = 43% est for overall effect: Z = 13.07 (P < 0.00001) Eavours (experimental) Eavours (cor	est for overall effect: Z = 9.16	(P < 0.00	001)							
leterogeneity: Chi <sup>#</sup> = 38.45, df = 22 (P = 0.02); i <sup>#</sup> = 43% est for overall effect: Z = 13.07 (P < 0.00001) Eavours (experimental) Eavours (cor	otal (95% CI)			330			296	100.0%	-0.65 [-0.75, -0.55]	•
est for overall effect: Z = 13.07 (P < 0.00001)		- 22 (P -	- 0.025		296		200			· · · ·
Favours respensively favours icon		•		1 - 43	1.10					
estion subgroup dimetences. Crin = 2.09, di = 2 (F = 0.20), F = 20.7 %				- 2 /P -	- 0.265	2-25	706			Favours [experimental] Favours [control]
	estion subdroup dilierences:	Cni= 2.	០១, ជា៖	- 2 (P =	- 0.20),	= 25.	/ 70			
IRF 8	JRE 8									

macroglobulin in sedentary male participants, activated the expression of angiopoietin-1, tyrosine kinase with immunoglobulin-like and EGF-like domains 2 genes, and muscle extracellular matrix genes, promoted angiogenesis and vascular stability, improved muscle structure and function, and enhanced aerobic fitness and exercise adaptability. This adaptation process allows the body to handle the same exercise intensity more efficiently. Consequently, compared to the rapid changes observed in the first 7 days, the increase in insulin sensitivity tends to level off, making the exercise effect less pronounced than in the 0-7 days group.


After more than 14 days of continuous aerobic exercise, longterm aerobic exercise can improve fat oxidation and insulin sensitivity, allowing the body to utilize more fat as an energy source during exercise, thereby improving exercise outcomes. This is consistent with van Wouwe et al. (2018), who observed that a 10-month circuit type integrated neuromuscular training reduced body mass 6%, body fat 5.5%, and increased fat-free mass by 1.2%–3.4%, strength 27.2% and endurance 26.8% in obese women. Also long term high-intensity hybrid-type neuromuscular training and home-based circuit training efficiently decreased waist-to-hip ratio by 4.6% and total cholesterol by 26.5%, while improving cardiometabolic health (Alexios et al., 2021; Al-Mhanna et al., 2024b; Badri Al-mhanna et al., 2024). Similarly, Mendham et al. (2015) found that 12 weeks of exercise and gym workouts can significantly reduce the body mass index, waist circumference, and waist-to-hip ratio of male patients with T2DM, as well as leptin levels. Compared to the control group, the area under the insulin curve and insulin resistance was also reduced, while insulin sensitivity increased. These findings suggest that continuous aerobic exercise for more than 14 days yields superior metabolic and glycemic control compared to shorter durations (7–14 days).

# 4.3 Different intensities of aerobic exercise can improve 24-hour mean blood glucose in patients with T2DM

This study concluded that low-intensity aerobic exercise cannot improve the 24-h mean blood glucose levels in patients with T2DM, whereas moderate- and high-intensity aerobic exercise can

	-	erimen			ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% Cl	IV, Fixed, 95% CI
4.5.1 29<									
K. M. Winding 2018(1)	7.6	1.3	12	8.8	1.7	7	0.5%	-1.20 [-2.66, 0.26]	
K. M. Winding 2018(2)	7.8	1.6	13	8.8	1.7	7	0.5%	-1.00 [-2.53, 0.53]	
M. Munan 2020(1)	7.5	0.7	13	7.5	0.6	12	4.1%	0.00 [-0.51, 0.51]	
M. Munan 2020(2)	7.3	0.9	14	7.5	0.6	12	3.2%	-0.20 [-0.78, 0.38]	
M. Munan 2020(3) Subtotal (95% CI)	7.6	0.8	13 65	7.5	0.6	12 50	3.5% 11 <b>.7</b> %	0.10 [-0.45, 0.65] - <b>0.11 [-0.42, 0.19]</b>	-
Heterogeneity: Chi <sup>z</sup> = 4.27, df:	= 4 (P = 0	.37); I <sup>z</sup>	= 6%						
Test for overall effect: Z = 0.74									
4.5.2 29-30									
É. Myette-Côté 2016	7	1.4	10	7.2	1.3	10	0.8%	-0.20 [-1.38, 0.98]	
K. Karstoft 2013(1)	8.1	0.8	12	8.3	1.1	8	1.4%	-0.20 [-1.09, 0.69]	
K. Karstoft 2013(2)	7.5	0.4	12	8.3	1.1	8		-0.80 [-1.60, -0.00]	
R. J. Manders 2010(1)	7.8	0.9	9	9.4	0.8	9		-1.60 [-2.39, -0.81]	
R. J. Manders 2010(2)	8.7	0.7	9	9.4	0.8	9		-0.70 [-1.39, -0.01]	
R. S. Metcalfe 2018(1)	7.74	1.1	11		1.05	11		-0.37 [-1.27, 0.53]	
R. S. Metcalfe 2018(2)		0.59	11		1.05	11	2.1%		
R. S. Metcalfe 2018(3)		0.87	11		1.05	11	1.6%	-0.58 [-1.39, 0.23]	
Subtotal (95% CI)			85			77	12.8%	-0.65 [-0.94, -0.36]	•
Heterogeneity: Chi <sup>2</sup> = 8.30, df:	= 7 (P = 0	.31); <b>P</b>	= 16%						
Test for overall effect: Z = 4.40	(P < 0.00	01)							
4.5.3 >30									
A. Marcotte-Chénard 2024(1)	7.02	1.01	14	8.88	1.5	14	1 206	-1.06 [-2.01, -0.11]	
A. Marcotte-Chénard 2024(1)		1.75	14	8.88	1.5	14	0.7%	-0.75 [-1.96, 0.46]	
D. J. Oberlin 2014		0.49	9		0.73	9		-0.64 [-1.21, -0.07]	
J. Haxhi 2016(1)		0.96	9		1.15	9	1.1%		
J. Haxhi 2016(2)		1.58	9		1.15	9	0.7%		
J. L. Rees 2019	7.4	1.5	37	7.3	1.4	26	2.0%	0.10 [-0.62, 0.82]	
J. W. van Dijk 2012(1)	8.3	0.3	30	9.1	0.4	30		-0.80 [-0.98, -0.62]	
J. W. van Dijk 2012(2)	8.3	0.3	30	9.1	0.4	30		-0.80 [-0.98, -0.62]	
Subtotal (95% CI)	0.0	0.0	152	0.1	0.1	141		-0.76 [-0.87, -0.64]	◆
Heterogeneity: Chi <sup>2</sup> = 9.21, df:	= 7 (P = 0	.24); l²	= 24%						-
Test for overall effect: Z = 12.4									
Fotal (95% CI)			302			268	100.0%	-0.67 [-0.77, -0.56]	•
Heterogeneity: Chi <sup>2</sup> = 36.86, d	f= 20 (P =	= 0.01)	<sup>2</sup> = 46	i%					
Test for overall effect: Z = 12.6									-2 -1 0 1 Favours [experimental] Favours [control]
						86.7%			Favours lexperimental Favours (control)

Forest plot showing the effect of aerobic exercise on 24-hour mean blood glucose in patients with T2DM and various BMIs.



effectively reduce blood glucose levels, with moderate-intensity aerobic exercise being more effective than high-intensity aerobic exercise. Similarity, Badri et al. (2024) reported that moderate to high-intensity exercise protocols were highly efficient for progressively increasing HDL-C levels, reducing body mass, and lowering cardiovascular disease risk factors in obesity individuals. These findings highlight the importance of moderate and high exercise intensity in managing cardiometabolic health in individuals with obesity or type 2 diabetes. Low-intensity exercise generally consumes less energy and cannot decrease blood sugar and, therefore, has no significant effect on blood sugar regulation (Zhang et al., 2021). For example, Munan et al. (2020) found that a single morning fasting walk did not significantly improve the 24hour mean blood glucose levels in patients with T2DM, and compared with the evening exercise group, the respiratory exchange rate was reduced, and compared with the afternoon exercise group, the blood glucose level was not significantly reduced.

Additionally, Batrakoulis et al. (2022b) suggested that an exercise intensity of 40%-60% of the oxygen consumption reserve is ideal for improving cardiometabolic health in patients with T2DM. Moderate-intensity exercise can moderately increase the body's energy expenditure, promote glucose utilization, and improve insulin sensitivity so that the body can more effectively utilize blood sugar, thereby reducing the 24-hour average blood sugar level. For example, Motahari-Tabari et al. (2014) found that 8 weeks of moderate-intensity aerobic exercise can significantly reduce the weight, waist circumference, hip circumference, BMI, plasma insulin, and insulin resistance of female patients with T2DM and promote blood glucose control. For high-intensity exercise, it can significantly increase energy expenditure and metabolic rate, but it can also have drastic adverse effects, making it less efficient than moderate intensity. High-intensity exercise triggers an immediate physiological stress response, causing a temporary increase in the levels of catecholamines (such as adrenaline and noradrenaline) (Liu et al., 2020). These hormones acutely promote the breakdown of glycogen in the liver, increase blood glucose concentration, which may temporarily counteract the hypoglycemic effect of exercise (Carletti et al., 2023).

# 4.4 Different frequencies of aerobic exercise can improve 24-hour mean blood glucose in patients with T2DM

This study found that aerobic exercise at different frequencies can improve the 24-hour mean blood glucose levels in patients with T2DM. The most effective exercise frequency is 2-4 times per week, followed by once per week, with 5-7 times per week having the least effect. The group of aerobic exercises 2-4 times a week can continuously improve the body's metabolic capacity during gradual adaptation, thereby achieving optimal blood glucose control. For example, Winding et al. (2018) found that 11 weeks of three-times-a-week HIIT can significantly reduce visceral fat mass, HbA1c, FBG, postprandial blood glucose, blood glucose variability, and HOMA-IR in patients with T2DM, and improve the overall health, body composition ratio and blood glucose control ability of patients. In contrast, exercising once per week primarily induces transient changes in blood glucose levels due to the lack of consistent metabolic stimulation and adaptation. Cerqueira et al. (2020) claimed that no significant changes were observed following either a single 45-minute session of moderate exercise or a 5-minute session of high-intensity exercise. Similarly, Haxhi et al. (2016) found that single session of moderate-intensity exercise only minimally decrease patients with T2DM 24-hour mean blood glucose from 7.29  $\pm$  1.15 to 7.21  $\pm$  0.96. Additionally, patients who exercise 5-7 times per week may experience stress responses

due to overtraining, leading to increased levels of stress hormones (such as cortisol), which could negatively impact blood glucose control (Hackney and Lane, 2015). Karstoft et al. (2013) found that 4 months of moderate-intensity exercise performed five times per week resulted in only a slight decrease in 24-hour mean blood glucose (from  $8.3 \pm 1.1$  to  $8.1 \pm 0.8$ ) in patients with T2DM. This suggests that excessively high exercise frequency may not provide additional benefits and could even be less effective than moderate frequencies.

# 4.5 Different durations of each aerobic exercise can improve the 24-hour mean blood glucose in patients with T2DM

This study found that aerobic exercise lasting less than 20 min cannot improve the 24-hour mean blood glucose of T2DM patients. In comparison, 20-40 min and 40-60 min of aerobic exercise can improve the 24-hour mean blood glucose level in patients with T2DM, with the 20-40-minute duration proving to be the most effective. When the duration of exercise is less than 20 min, exercise may not be able to fully activate the uptake and utilization of glucose in muscles and thus fail to change blood glucose levels throughout the day significantly. For example, Metcalfe et al. (2018) found that a single  $10 \times 1$ -minute HIIT can significantly reduce the duration of hyperglycemia in patients with type 2 diabetes, while blood glucose variability does not significantly change from the 24-hour average blood glucose. Second, 20-40 min may be the best combination of intensity and time. Sufficient time allows the body's energy metabolism to be fully activated, improving oxidative stress while not causing excessive stress or fatigue due to excessive duration. For example, Haxhi et al. (2016) found that 40 min of moderateintensity aerobic exercise significantly reduced the duration of hyperglycemia and urinary isoprostanes, alleviated oxidative stress, and lowered the 24-hour mean blood glucose. Similarity, On the other hand, prolonged exercise durations of 40-60 min may lead to excessive fatigue, potentially hindering long-term metabolic improvements (Liu et al., 2024).

### 4.6 Aerobic exercise can improve the 24hour mean blood glucose in patients with T2DM and various BMIs

This study concluded that aerobic exercise cannot improve the 24-hour mean blood glucose in patients with T2DM who have a BMI below 29 kg/m<sup>2</sup>. In contrast, aerobic exercise can improve these levels in patients with a BMI between 29 and 30 kg/m<sup>2</sup>, and those with a BMI above 30 kg/m<sup>2</sup>, with the most significant effect observed in patients with a BMI above 30 kg/m<sup>2</sup>. A BMI below 29 kg/m<sup>2</sup> generally indicates a lower body fat percentage; however, individuals with this BMI may still experience insulin resistance or other metabolic issues, which are not solely related to body fat. Consequently, their response to exercise in terms of blood glucose control may be less pronounced (Butryn et al., 2019). Patients with a BMI between 29k and 30 kg/m<sup>2</sup>, and those with a BMI above 30 kg/m<sup>2</sup>, often face greater challenges in managing selfmonitoring, inhibitory control, and planning abilities. Despite the

substantial effort required, the benefits of exercise, including fat loss and overall metabolic improvement, are typically more pronounced in these groups. Batrakoulis (2022a) and Batrakoulis (2022b) found that yoga activity and Pilates Training can efficiently reduce reductions in body weight, BMI, body fat, waist size, waist-to-hip ratio and lipid metabolism in overweight and obese individuals. This is likely due to the greater impact of exercise on body composition and metabolic function in individuals with higher BMIs, leading to more significant improvements in blood glucose control (Butryn et al., 2019).

### 4.7 Limitations

This study is the first meta-analysis to analyze the effect of aerobic exercise on 24-hour mean blood glucose in patients with T2DM as measured by CGM. It provides insights into the overall effect of aerobic exercise on 24-hour mean blood glucose and HbA1c in T2DM patients, as well as a detailed subgroup analysis of how different exercise periods, intensities, frequencies, and durations affect patients with varying BMIs. However, this meta-analysis still has some limitations. First, the studies we included were randomized controlled trials (RCTs) with relatively small sample sizes, which resulted in an underrepresented patient population and may have introduced selection bias. More high-quality RCTs are needed to explore their effectiveness in the future. Secondly, since diabetes and its complications are chronic diseases, most current research is based on short- and medium-term studies, and there is a lack of research data on long-term interventions. Therefore, future research should focus on long-term interventions.

### 5 Conclusion

- 5.1. Aerobic exercise can improve 24-hour mean blood glucose and HbA1c in patients with T2DM.
- 5.2. Aerobic exercise for 0–7 days, 7–14 days, and >14 days can improve the 24-hour mean blood glucose in patients with T2DM.
- 5.3. Moderate- to high-intensity aerobic exercise can improve the 24-hour mean blood glucose level in patients with T2DM patients, whereas low-intensity exercise cannot.
- 5.4. Aerobic exercise once a week, as well as 2–4 times and 5–7 times per week, can improve the 24-hour mean blood glucose of T2DM patients.

### References

Alexios, B., Jamurtas, A. Z., Draganidis, D., Georgakouli, K., Tsimeas, P., Poulios, A., et al. (2021). Hybrid neuromuscular training improves cardiometabolic health and alters redox status in inactive overweight and obese women: a randomized controlled trial. *Antioxidants* 10 (10), 1601. doi:10.3390/antiox10101601

Al-Mhanna, S. B., Batrakoulis, A., Mohamed, M., Alkhamees, N. H., Sheeha, B. B., Ibrahim, Z. M., et al. (2024b). Home-based circuit training improves blood lipid profile, liver function, musculoskeletal fitness, and health-related quality of life in overweight/ obese older adult patients with knee osteoarthritis and type 2 diabetes: a randomized controlled trial during the COVID-19 pandemic. *BMC Sports Sci. Med. Rehabilitation* 16 (1), 125. doi:10.1186/s13102-024-00915-4

Al-Mhanna, S. B., Batrakoulis, A., Wan Ghazali, W. S., Mohamed, M., Aldayel, A., Alhussain, M. H., et al. (2024a). Effects of combined aerobic and resistance training on

- 5.5. Each 20–40 and 40–60 min of aerobic exercise can improve the 24-hour mean blood glucose in patients with T2DM, whereas the 0–20 min of aerobic exercise cannot improve it.
- 5.6. Aerobic exercise can improve the 24-hour mean blood glucose in patients with T2DM who have a BMI between 29 and 30 and above 30 kg/m<sup>2</sup> but not in those with a BMI below 29.

### Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

### Author contributions

CW: Data curation, Formal Analysis, Methodology, Software, Validation, Visualization, Writing-original draft, Writing-review and editing. ST: Conceptualization, Investigation, Resources, Writing-review and editing.

### Funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

### Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

### Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

glycemic control, blood pressure, inflammation, cardiorespiratory fitness and quality of life in patients with type 2 diabetes and overweight/obesity: a systematic review and meta-analysis. *PeerJ* 12, e17525. doi:10.7717/peerj.17525

Al-Mhanna, S. B., Rocha-Rodriguesc, S., Mohamed, M., Batrakoulis, A., Aldhahi, M. I., Afolabi, H. A., et al. (2023). Effects of combined aerobic exercise and diet on cardiometabolic health in patients with obesity and type 2 diabetes: a systematic review and meta-analysis. *BMC Sports Sci. Med. Rehabilitation* 15 (1), 165. doi:10.1186/s13102-023-00766-5

A'Naja, M. N., Reed, R., Sansone, J., Alexios, B., McAvoy, C., and Parrott, M. W. (2024). 2024 ACSM Worldwide fitness trends: future directions of the health and fitness industry. *ACSM's Health and Fit. J.* 28, 14–26. doi:10.1249/FIT. 00000000000933

Badri, A.-mhanna S., Leão, C., Wan Ghazali, W. S., Mohamed, M., Batrakoulis, A., Abiola Afolabi, H., et al. (2024). Impact of Exercise on High-Density Lipoprotein Cholesterol in adults with overweight and obesity: a narrative review. *Ann. Appl. Sport Sci.* 12, 0. doi:10.61186/aassjournal.1300

Badri Al-mhanna, S., Wan Ghazali, W. S., Batrakoulis, A., Alkhamees, N. H., Drenowatz, C., Mohamed, M., et al. (2024). The impact of various types of exercise on lipid metabolism in patients with type 2 diabetes and concurrent overweight/obesity: a narrative review. *Ann. Appl. Sport Sci.* 12 (S2), 0. doi:10.61186/aassjournal.1324

Batrakoulis, A. (2022a). Psychophysiological adaptations to yoga practice in overweight and obese individuals: a topical review. *Diseases* 10 (4), 107. doi:10.3390/ diseases10040107

Batrakoulis, A. (2022b). Psychophysiological adaptations to Pilates training in overweight and obese individuals: a topical review. *Diseases* 10 (4), 71. doi:10.3390/diseases10040071

Batrakoulis, A., and Fatouros, I. G. (2022). Psychological adaptations to high-intensity interval training in overweight and obese adults: a topical review. *Sports* 10 (5), 64. doi:10.3390/sports10050064

Batrakoulis, A., Jamurtas, A. Z., and Fatouros, I. G. (2021). High-intensity interval training in metabolic diseases: physiological adaptations. *ACSM's Health and Fit. J.* 25 (5), 54–59. doi:10.1249/FIT.00000000000703

Batrakoulis, A., Jamurtas, A. Z., and Fatouros, I. G. (2022b). Exercise and type II diabetes mellitus: a brief guide for exercise professionals. *Strength and Cond. J.* 44 (6), 64–72. doi:10.1519/ssc.00000000000731

Batrakoulis, A., Jamurtas, A. Z., Metsios, G. S., Perivoliotis, K., Liguori, G., Feito, Y., et al. (2022a). Comparative efficacy of 5 exercise types on cardiometabolic health in overweight and obese adults: a systematic review and network meta-analysis of 81 randomized controlled trials. *Circulation Cardiovasc. Qual. Outcomes* 15 (6), e008243. doi:10.1161/circoutcomes.121.008243

Butryn, M. L., Martinelli, M. K., Remmert, J. E., Roberts, S. R., Zhang, F., Forman, E. M., et al. (2019). Executive functioning as a predictor of weight loss and physical activity outcomes. *Ann. Behav. Med.* 53 (10), 909–917. doi:10.1093/abm/kaz001

Carletti, L., Araujo, I. Z., Neves, L. N. S., Gasparini Neto, V. H., and Leite, R. D. (2023). Limiar glicêmico: validade com limiar de lactato e concordância com a variabilidade da frequência cardíaca. *Rev. Bras. Fisiol. do Exercício* 21 (6), 329–339. doi:10.33233/rbfex. v21i6.5409

Cerqueira, É., Marinho, D. A., Neiva, H. P., and Lourenço, O. (2020). Inflammatory effects of high and moderate intensity exercise—a systematic review. *Front. Physiology* 10, 1550. doi:10.3389/fphys.2019.01550

Dastbarhagh, H., Kargarfard, M., Abedi, H., Bambaeichi, E., and Nazarali, P. (2019). Effects of food restriction and/or aerobic exercise on the GLUT4 in type 2 diabetic male rats. *Int. J. Prev. Med.* 10, 139. doi:10.4103/ijpvm.IJPVM\_383\_17

Edelman, S. V., Argento, N. B., Pettus, J., and Hirsch, I. B. (2018). Clinical implications of real-time and intermittently scanned continuous glucose monitoring. *Diabetes Care* 41 (11), 2265–2274. doi:10.2337/dc18-1150

Hackney, A. C., and Lane, A. R. (2015). Exercise and the regulation of endocrine hormones. *Prog. Mol. Biol. Transl. Sci.* 135, 293–311. doi:10.1016/bs.pmbts.2015.07.001

Haxhi, J., Leto, G., di Palumbo, A. S., Sbriccoli, P., Guidetti, L., Fantini, C., et al. (2016). Exercise at lunchtime: effect on glycemic control and oxidative stress in middle-aged men with type 2 diabetes. *Eur. J. Appl. physiology* 116 (3), 573–582. doi:10.1007/s00421-015-3317-3

Karstoft, K., Clark, M. A., Jakobsen, I., Müller, I. A., Pedersen, B. K., Solomon, T. P. J., et al. (2017). The effects of 2 weeks of interval vs continuous walking training on glycaemic control and whole-body oxidative stress in individuals with type 2 diabetes: a controlled, randomised, crossover trial. *Diabetologia* 60 (3), 508–517. doi:10.1007/ s00125-016-4170-6

Karstoft, K., Winding, K., Knudsen, S. H., Nielsen, J. S., Thomsen, C., Pedersen, B. K., et al. (2013). The effects of free-living interval walking training on glycemic control, body composition, and physical fitness in type 2 diabetic patients A randomized, controlled trial. *Diabetes Care* 36 (2), 228–236. doi:10.2337/dc12-0658

Li, X., Chang, P., Wu, M., Jiang, Y., Gao, Y., Chen, H., et al. (2024). Effect of tai Chi vs aerobic exercise on blood pressure in patients with prehypertension: a randomized clinical trial. *JAMA Netw. Open* 7 (2), e2354937. doi:10.1001/jamanetworkopen.2023. 54937

Liu, Y., Dong, G., Zhao, X., Huang, Z., Li, P., and Zhang, H. (2020). Post-exercise effects and long-term training adaptations of hormone sensitive lipase lipolysis induced by high-intensity interval training in adipose tissue of mice. *Front. Physiol.* 11, 535722. doi:10.3389/fphys.2020.535722

Liu, Y., Feng, Z., Hu, Y., Xu, X., Kuang, T., and Liu, Y. (2024). Polysaccharides derived from natural edible and medicinal sources as agents targeting exercise-induced fatigue: a review. *Int. J. Biol. Macromol.* 256 (Pt 1), 128280. doi:10.1016/j.ijbiomac.2023.128280

Manders, R. J. F., Van Dijk, J. W. M., and Van Loon, L. J. C. (2010). Low-intensity exercise reduces the prevalence of hyperglycemia in type 2 diabetes. *Med. and Sci. Sports and Exerc.* 42 (2), 219–225. doi:10.1249/MSS.0b013e3181b3b16d

Marcotte-Chénard, A., Tremblay, R., Deslauriers, L., Geraldes, P., Gayda, M., Christou, D., et al. (2024). Comparison of 10 × 1-minute high-intensity interval training (HIIT) versus 4 × 4-minute HIIT on glucose control and variability in females with type 2 diabetes. *Appl. Physiology Nutr. Metabolism* 49 (4), 487–500. doi:10.1139/apnm-2023-0326

Mendham, A. E., Duffield, R., Marino, F., and Coutts, A. J. (2015). A 12-week sportsbased exercise programme for inactive Indigenous Australian men improved clinical risk factors associated with type 2 diabetes mellitus. *J. Sci. Med. Sport* 18 (4), 438–443. doi:10.1016/j.jsams.2014.06.013

Metcalfe, R. S., Fitzpatrick, B., Fitzpatrick, S., McDermott, G., Brick, N., McClean, C., et al. (2018). Extremely short duration interval exercise improves 24-h glycaemia in men with type 2 diabetes. *Eur. J. Appl. physiology* 118 (12), 2551–2562. doi:10.1007/s00421-018-3980-2

Motahari-Tabari, N., Ahmad, S. M., Shirzad, E. A. M., Yousefi-Abdolmaleki, E., and Teimourzadeh, M. (2014). The effect of 8 weeks aerobic exercise on insulin resistance in type 2 diabetes: a randomized clinical trial. *Glob. J. Health Sci.* 7 (1), 115–121. doi:10. 5539/gjhs.v7n1p115

Munan, M., Dyck, R. A., Houlder, S., Yardley, J. E., Prado, C. M., Snydmiller, G., et al. (2020). Does exercise timing affect 24-hour glucose concentrations in adults with type 2 diabetes? A follow up to the exercise-physical activity and diabetes glucose monitoring study. *Can. J. Diabetes* 44 (8), 711–718.e1. doi:10.1016/j.jcjd.2020.05.012

Myette-Côté, É., Terada, T., and Boulé, N. G. (2016). The effect of exercise with or without metformin on glucose profiles in type 2 diabetes: a pilot study. *Can. J. diabetes* 40 (2), 173–177. doi:10.1016/j.jcjd.2015.08.015

Oberlin, D. J., Mikus, C. R., Kearney, M. L., Hinton, P. S., Manrique, C., Leidy, H. J., et al. (2014). One bout of exercise alters free-living postprandial glycemia in type 2 diabetes. *Med. Sci. sports Exerc.* 46 (2), 232–238. doi:10.1249/MSS.0b013e3182a54d85

Park, J. H., Moon, J. H., Kim, H. J., Kong, M. H., and Oh, Y. H. (2020). Sedentary lifestyle: overview of updated evidence of potential health risks. *Korean J. Fam. Med.* 41 (6), 365–373. doi:10.4082/kjfm.20.0165

Qian, J., Xiao, Q., Walkup, M. P., Coday, M., Erickson, M. L., Unick, J., et al. (2023). Association of timing of moderate-to-vigorous physical activity with changes in glycemic control over 4 Years in adults with type 2 diabetes from the look AHEAD trial. *Diabetes Care* 46 (7), 1417–1424. doi:10.2337/dc22-2413

Rees, J. L., Chang, C. R., François, M. E., Marcotte-Chénard, A., Fontvieille, A., Klaprat, N. D., et al. (2019). Minimal effect of walking before dinner on glycemic responses in type 2 diabetes: outcomes from the multi-site E-PAraDiGM study. *Acta Diabetol.* 56 (7), 755–765. doi:10.1007/s00592-019-01358-x

Remelli, F., Ceresini, M. G., Trevisan, C., Noale, M., and Volpato, S. (2022). Prevalence and impact of polypharmacy in older patients with type 2 diabetes. *Aging Clin. Exp. Res.* 34 (9), 1969–1983. doi:10.1007/s40520-022-02165-1

Sartore, G., Ragazzi, E., Caprino, R., and Lapolla, A. (2023). Long-term HbA1c variability and macro-/micro-vascular complications in type 2 diabetes mellitus: a metaanalysis update. *Acta Diabetol.* 60 (6), 721–738. doi:10.1007/s00592-023-02037-8

Timmons, J. A., Jansson, E., Fischer, H., Gustafsson, T., Greenhaff, P. L., Ridden, J., et al. (2005). Modulation of extracellular matrix genes reflects the magnitude of physiological adaptation to aerobic exercise training in humans. *BMC Biol.* 3, 19. doi:10.1186/1741-7007-3-19

van Dijk, J. W., Tummers, K., Stehouwer, C. D. A., Hartgens, F., and van Loon, L. J. C. (2012). Exercise Therapy in Type 2 Diabetes Is daily exercise required to optimize glycemic control? *Diabetes Care* 35 (5), 948–954. doi:10.2337/dc11-2112

van Wouwe, J. P., Batrakoulis, A., Jamurtas, A. Z., Georgakouli, K., Draganidis, D., Deli, C. K., et al. (2018). High intensity, circuit-type integrated neuromuscular training alters energy balance and reduces body mass and fat in obese women: a 10-month training-detraining randomized controlled trial. *Plos One* 13 (8), e0202390. doi:10.1371/ journal.pone.0202390

Winding, K. M., Munch, G. W., Iepsen, U. W., Van Hall, G., Pedersen, B. K., and Mortensen, S. P. (2018). The effect on glycaemic control of low-volume high-intensity interval training versus endurance training in individuals with type 2 diabetes. *Diabetes, Obes. and metabolism* 20 (5), 1131–1139. doi:10.1111/dom.13198

Wu, C. Z., Yuan, Y. H., Liu, H. H., Li, S. S., Zhang, B. W., Chen, W., et al. (2020). Epidemiologic relationship between periodontitis and type 2 diabetes mellitus. *BMC Oral Health* 20 (1), 204. doi:10.1186/s12903-020-01180-w

Yang, H., Cheng, Y., Zhao, Y., Chen, Y., Li, Z., and Mu, S. (2024). Exercise combing with short-term continuous glucose monitoring promotes diabetes health self-care scale and glycemic control in individuals with type 2 diabetes. *Sci. Sports* 39, 483–488. doi:10. 1016/j.scispo.2023.11.006

Zhang, M., Zucatti, K. P., Teixeira, P. P., Correia, P. E., Wayerbacher, L. F., Spiazzi, B. F., et al. (2023). Cancer outcomes among prediabetes and type 2 diabetes populations with dietary and physical activity-based lifestyle interventions. *J. Clin. Endocrinol. Metab.* 108 (8), 2124–2133. doi:10.1210/clinem/dgad123

Zhang, Q. Q., Ding, Y. J., Zhang, J. J., and Wang, L. (2021). Effects of acute exercise with different intensities on glycemic control in patients with type 2 diabetes mellitus. *Acta Endocrinol. (Buchar)* 17 (2), 212–218. doi:10.4183/aeb.2021.212